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ABSTRACT 
Vitamin D is an essential fat-soluble nutrient that plays a critical role in calcium 
homeostasis among women of childbearing age. Vitamin D has also been linked to pregnancy 
health outcomes and may have long-term effects on maternal and child health. Nevertheless, the 
effects of human pregnancy on vitamin D requirements are poorly understood, and very little is 
known about placental vitamin D metabolism and its putative effects on maternal circulating pool 
of vitamin D. The impact of maternal vitamin D status on maternal and fetal bone health is also 
unclear. As such, my dissertation sought to advance understanding of vitamin D metabolism in 
human pregnancy, to characterize the effect of the placenta on maternal circulating vitamin D 
metabolites, and to examine the impact of maternal vitamin D status on maternal and fetal bone 
health.  
To achieve these aims, biomarkers of vitamin D status/metabolism were measured in blood 
and placental tissue obtained from third-trimester pregnant women who participated in a long-term 
controlled feeding study and consumed equivalent intakes of vitamin D, calcium, and phosphorus. 
A human placental cell culture model was also used to characterize vitamin D uptake, intracellular 
metabolism, secretion, and to inform the interpretation of the human study data.  
   
The data showed that pregnant women had 30-100% higher (P<0.01) circulating vitamin 
D metabolites [25(OH)D, 1,25(OH)2D, 3-epi-25(OH)D3, and 25(OH)D:24,25(OH)2D] than 
nonpregnant women suggesting that the placenta may be a source of vitamin D metabolites during 
pregnancy. This notion was supported by the significant associations (P<0.04) between maternal 
circulating vitamin D metabolites and placental mRNA abundance of vitamin D machinery (LRP2, 
CUBN, CYP2R1, CYP27B1, and CYP24A1), and by the endogenous production and secretion of 
25(OH)D3 by placental trophoblasts in vitro. The data also showed that maternal 25(OH)D, free 
25(OH)D, 1,25(OH)2D, and epi-25(OH)D3 were inversely associated (P<0.04) with maternal bone 
resorption markers (deoxypyridinoline, NTx, and iPTH). 
Overall, these data collectively suggest that pregnancy increases circulating pools of 
maternal vitamin D metabolites, in part, through the placenta which can produce and secrete all 
forms of vitamin D metabolites including 25(OH)D3. These findings also imply that achieving 
higher maternal concentrations of circulating vitamin D metabolites during pregnancy may 
attenuate maternal bone loss.   
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PREFACE 
SPECIFIC AIMS 
The overarching goal of my dissertation research was to advance current understanding of 
maternal vitamin D metabolism in human pregnancy with an emphasis on the placenta, and to 
delineate the effects of maternal vitamin D status on maternal and fetal bone health outcomes.  
Aim 1: To test the hypothesis that the reproductive state (i.e., pregnancy and lactation) will 
alter blood biomarkers of vitamin D metabolism. This aim was achieved by measuring 
circulating concentrations of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D 
[1,25(OH)2D], vitamin D binding protein (DBP), 24,25-dihydroxyvitamin D [24,25(OH)2D], and 
C3 epimer of 25(OH)D3, and by estimating free 25(OH)D, the 25(OH)D:24,25(OH)2D ratio, and 
the 1,25(OH)2D:25(OH)D ratio in pregnant, lactating and control women who consumed 
equivalent amounts of vitamin D and other nutrients. Results are presented in chapter 1. 
Aim 2: To test the hypothesis that placenta metabolizes vitamin D and contributes to the 
changes in maternal circulating vitamin D metabolites. This aim was achieved by measuring 
placental gene expression levels of the megalin-cubilin receptor (LRP2 and CUBN), 25-
hydroxylase (CYP2R1), 1α-hydroxylase (CYP27B1), and 24-hydroxylase (CYP24A1) as well as 
the metabolite concentrations of vitamin D metabolites including 25(OH)D from placental tissues. 
In addition, associations with maternal circulating vitamin D metabolites were examined. Results 
are presented in chapter 2. 
Aim 3: To examine the uptake and metabolic fate of vitamin D [i.e., vitamin D, 25(OH)D, 
1,25(OH)2D, and 24,25(OH)2D] in human placental trophoblasts. This aim was achieved by 
employing a human placental cell culture model using stable isotope methodology. Results are 
presented in chapter 2. 
 xiv 
Aim 4: To test the hypothesis that maternal serum 25(OH)D concentrations are associated 
with maternal and fetal markers of bone metabolism. This aim was achieved by examining 
associations between maternal markers of vitamin D status [i.e., 25(OH)D, 1,25(OH)2D, 
24,25(OH)2D, free 25(OH)D, and C3 epimer of 25(OH)D3) and maternal/fetal biochemical 
markers of bone metabolism (i.e., osteocalcin, alkaline phosphatase, carboxy-terminal cross-
linking telopeptide of type 1 collagen, amino-terminal cross-linking telopeptide of type 1 collagen, 
deoxypyridinoline, and parathyroid hormone) in pregnant and control women consuming 
controlled amounts of vitamin D-related nutrient such as calcium and phosphorus. Results are 
presented in chapter 3. 
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OUTPUT  
This dissertation research yielded two published peer-reviewed articles (Chapter 1 and 3) and one 
original research manuscript which will be submitted for publication within the next few months 
(Chapter 2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi 
BACKGROUND, SIGNIFICANCE AND RATIONALE 
Vitamin D requirement and the prevalence of vitamin D inadequacy in pregnant and 
lactating women 
Due to uncertainties about the specific biological roles of vitamin D during pregnancy and 
lactation, no incremental increases in the vitamin D RDA (relative to women of reproductive age) 
were made by the Institute of Medicine (IOM) for pregnant and lactating women (1,2). Thus, 600 
IU vitamin D/d is currently recommended for all women of childbearing age including those who 
are pregnant or breastfeeding. Nevertheless, vitamin D inadequacy among pregnant and lactating 
women is highly prevalent worldwide with the percentage of inadequacy varying by race, 
ethnicity, or latitude/country of residence (3–5). Moreover, several epidemiologic and case-control 
studies have shown that low vitamin D status increases the risk for adverse reproductive outcomes 
such as impaired fetal/neonatal growth and bone development, preeclampsia, higher risk of 
Cesarean delivery, and bacterial vaginosis (6). Therefore, it is important to quantify the effect 
of the reproductive state (i.e., pregnancy and lactation) on vitamin D metabolism and 
establish vitamin D recommendations for pregnant and lactating women that promote 
optimal health of both mother and fetus/infant. 
 
Vitamin D metabolism and its classical endocrine function 
Vitamin D is a unique essential nutrient because it has an exogenous (dietary) source and 
an endogenous source when synthesized by the skin. The body obtains vitamin D in the form of 
vitamin D2 and D3 by the intake of fatty fish, egg yolk, vitamin D fortified foods, or dietary 
supplements. When exposed to ultraviolet B (UVB) with wavelengths between 290 and 320 nm, 
7-dehydrocholesterol is converted to previtamin D3 in the epidermis, and subsequently thermally 
isomerized to vitamin D3 (7). Irrespective of the source, both dietary and endogenously produced 
 xvii 
vitamin D are ultimately carried to the liver (1). Dietary vitamin D is absorbed in the intestine and 
packaged with other lipids into a chylomicron. The chylomicron enters into the systemic 
circulation via the lymph and is then metabolized to a chylomicron remnant by lipoprotein lipase 
in the peripheral tissues. In turn, this vitamin D-containing remnant is transported into the liver. 
On the other hand, endogenously produced vitamin D in the skin diffuses across subcutaneous 
adipose layer into the blood, binds to vitamin D binding protein (DBP), and is taken up by the liver.  
In the liver, vitamin D is hydroxylated to 25-hydroxyvitamin D [25(OH)D] by microsomal 
25-hydroxylase, CYP2R1 (the major one) or mitochondrial 25-hydroxylase, CYP27A1. 25(OH)D 
can then be released into the blood where it mostly binds to DBP; small amounts of free 25(OH)D 
can also be found in circulation (8). Because 25(OH)D is biologically inert, it must be converted 
to an active form to perform its classical endocrine function. Renal proximal tubular cells take up 
DBP-bound 25(OH)D from the glomerular ultrafiltrate through endocytic receptors, the megalin-
cubilin receptor complex, and the second hydroxylation to 1,25-dihydroxyvitamin D 
[1,25(OH)2D], also called calcitriol, occurs by mitochondrial 1α-hydroxylase (CYP27B1). Once 
produced, the biologically active form of vitamin D, 1,25(OH)2D, is released into circulation where 
it binds to DBP and enters the classical target tissues such as bone, intestine, and kidney. In cells 
of the target tissues expressing vitamin D receptor (VDR), 1,25(OH)2D binds to VDR in the 
nucleus and VDR forms a heterodimer with retinoid X receptor (RXR). Next, this 1,25(OH)2D-
VDR-RXR heterodimeric complex binds to a vitamin D response element (VDRE) located in 
vitamin D-dependent genes to regulate the expression of these genes with functions in calcium and 
phosphate homeostasis (9). Through this action, vitamin D is intimately involved in bone 
development and maintenance (10) (Figure P.1). Other physiologic processes that are influenced 
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by 1,25(OH)2D include the immune system, insulin secretion, blood pressure, and fetal 
development (11).  
The degradation of 1,25(OH)2D and 25(OH)D is carried out by mitochondrial 24-
hydroxlyase (CYP24A1), which is found in all target tissues and produces inactive metabolites 
such as calcitroic acid and 24,25-dihydroxyvitamin D [24,25(OH)2D], respectively (Figure P.1). 
When the 1,25(OH)2D-VDR-RXR complex binds to VDRE in CYP24A1 gene, 1,25(OH)2D can 
stimulate its degradation through activation of the catabolic enzyme CYP24A1. The produced 
catabolic metabolites are then excreted through the bile in the feces (12).  
As 1,25(OH)2D is a hormone, the metabolic step of 1,25(OH)2D synthesis is tightly 
regulated in the body, and its half-life is about 4 hours. In contrast, the synthesis of 25(OH)D is 
less regulated than the synthesis of 1,25(OH)2D, and it has a longer half-life, approximately three 
weeks. In addition, its synthesis depends on the levels of the substrate, vitamin D. For these reasons, 
25(OH)D is the major circulating form of vitamin D and serum concentration of 25(OH)D is 
currently the best biomarker of vitamin D status as it reflects the total exposure from the diet and 
cutaneous synthesis (13).  
 
 
 
 
 
 
 
 
 xix 
 
 
 
 
 
 
Figure P.1. Overview of vitamin D metabolism and its classical endocrine function. Both 
endogenously synthesized vitamin D in the skin and absorbed dietary vitamin D in the intestine 
are transported into the liver and hydroxylated to 25(OH)D by 25-hydroxylase. Released 25(OH)D 
binds to DBP and travels to the kidney where the second hydroxylation by 1a-hydroxylase to 
1,25(OH)2D occurs. 1,25(OH)2D is released into circulation, and then can enter and act on the 
target cells through a VDR-mediated transcriptional regulation.   
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Vitamin D metabolism in pregnancy and lactation 
Pregnancy is characterized by a dramatic increase in two maternal circulating vitamin D 
biomarkers: about a 150% increase in DBP (14–16) and a 200% increase in 1,25(OH)2D (14,17–
19). However, the underlying mechanisms of these changes during pregnancy are largely 
unknown.   
Data on the effect of pregnancy on maternal circulating 25(OH)D is mixed among studies 
with reports of no changes (17,15,20), increases (14,18,21,22), or decreases (19,23). A meta-
analysis (17) including 24 studies in pregnant and nonpregnant women reported no difference in 
serum 25(OH)D between these groups. However, most of the studies were conducted prior to 
current standardized efforts to reduce large inter-laboratory variations in measuring serum 
25(OH)D such as National Institute of Standards and Technology (NIST) Standard Reference 
Material (SRM) for serum 25(OH)D or the Vitamin D External Quality Assessment Scheme 
(DEQAS). As such, substantial heterogeneity among the studies that used different quantification 
methods of 25(OH)D raises concerns regarding the validity of these results. Moreover, most 
studies did not adequately assess maternal vitamin D intake and/or intake of other relevant 
nutrients (i.e., calcium and phosphorus). Because vitamin D intake affects serum 25(OH)D, a 
biomarker of exposure to vitamin D, and dietary calcium and phosphorous interact with vitamin 
D metabolism, the contradictory results of 25(OH)D during pregnancy may have arisen from 
differences in the dietary intake of these nutrients across the studies. Some studies on the effect of 
lactation on maternal vitamin D metabolism have reported decreases in circulating 1,25(OH)2D, 
DBP, and 25(OH)D (15,24,25). However, it is unclear if vitamin D status of lactating women 
differs from that of a nonpregnant, nonlactating woman under conditions of equivalent intakes of 
vitamin D and related nutrients.  
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Finally, changes in additional maternal circulating vitamin D metabolites including 
24,25(OH)2D in pregnancy and lactation have been less explored compared to 1,25(OH)2D, DBP, 
and 25(OH)D. Taken together, human feeding studies which experimentally control the 
intake of vitamin D and related nutrients are needed to more fully understand the influence 
of pregnancy and lactation on vitamin D metabolism and requirements. 
 
Placental vitamin D metabolism and its possible contribution to circulating vitamin D 
metabolites including 25(OH)D 
Very little is known about human placental vitamin D metabolism (26). Moreover, the 
mechanism leading to alterations in maternal vitamin D metabolism during pregnancy is largely 
unexplored. However, the placenta is emerging as a potential mediator of the changes in maternal 
circulating vitamin D metabolites as it expresses all components of the vitamin D metabolic 
pathway such as the megalin-cubilin receptor complex (LRP2 and CUBN, respectively) (27,28), 
1α-hydroxylase (CYP27B1) (29–31), 24-hydroxlyase (CYP24A1) (31,32), and 25-hydroxylase 
(CYP2R1) (31).    
The megalin-cubilin receptor complex was initially identified in the kidney proximal 
tubules (33). However, it was later found to be located in the membrane of tissues other than the 
kidney, including the placenta (27,28). In the kidney, DBP-bound 25(OH)D is taken up through 
the megalin-cubilin receptor-mediated endocytosis and subsequently used to produce 1,25(OH)2D 
(34). Thus, placental possession of the megalin-cubilin receptors (27,28) along with the findings 
of elevations of DBP and 1,25(OH)2D during pregnancy (15,16) could suggest that the placenta 
may be a source of the bioactive form of vitamin D. 
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The placenta also has several enzymes that comprise the vitamin D metabolic pathway 
such as CYP27B1 (29–31), CYP24A1 (31,32), and CYP2R1 (31). Furthermore, in vitro production 
of 1,25(OH)2D (29,35) and 24,25(OH)2D (35,36) by CYP27B1 and CYP24A1, respectively, was 
reported in human placental cells. The placentally produced 1,25(OH)2D was further confirmed to 
be capable of entering maternal circulation as nephrectomized pregnant rats exhibited placental 
release of [3H]-1,25(OH)2D into maternal circulation after injecting [
3H]-25(OH)D (37), and 
nephrotic pregnant women who discontinued her oral treatment with 1,25(OH)2D for 3 weeks did 
not show decreases in serum 1,25(OH)2D concentrations (a half-life of ~4 hours) (38). In contrast 
to the placental production of 1,25(OH)2D and 24,25(OH)2D which have been established, whether 
the placenta produces 25(OH)D from vitamin D by CYP2R1 and contributes to the maternal 
circulating pool of this vitamin metabolite remain unknown. Lastly, it is also unclear about the 
impact of placental vitamin D metabolism on additional circulating vitamin D metabolites such as 
24,25(OH)2D. 
In sum, the placenta appears to play a central role in regulating vitamin D metabolism 
and status during pregnancy. However, additional human studies are needed to better 
understand placental vitamin D metabolism and its contribution to the modification of 
maternal circulating vitamin D metabolites. Unfortunately, studies in human pregnancies 
examining this possibility have left out key measurements including placental concentrations of 
vitamin D metabolites. In addition, no study has systematically examined uptake and metabolic 
fate of all forms of vitamin D such as parent vitamin D, 25(OH)D, 1,25(OH)2D, and 24,25(OH)2D 
in human placental trophoblasts in vitro.  
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The impact of maternal vitamin D status on maternal and fetal bone health outcomes 
During pregnancy, ~25-30g of calcium is transferred to the fetus, and 99% of it is used to 
mineralize the skeleton. To meet most of this demand for calcium, maternal intestinal calcium 
absorption doubles early in pregnancy (39). Maternal bone resorption may also occur to provide 
calcium to the circulation and ultimately the fetus, although the extent to which mother’s bone 
resorption contributes calcium to the developing fetus is unclear (40). Because vitamin D is known 
to influence the aforementioned physiological processes (i.e., intestinal calcium absorption and 
bone resorption) in a normal nonpregnant state (1), one might expect that ensuring sufficient 
vitamin D would be critical in meeting the high demands for calcium during gestation. However, 
whether this classical endocrine function of vitamin D in bone health is operational during 
pregnancy is uncertain. 
In animal studies, vitamin D-deficient pregnant rats and VDR knockout pregnant mice 
exhibited increased calcium absorption in the intestine (41–43). Moreover, fetuses from severely 
vitamin D-deficient or VDR knockout mice showed normal calcium homeostasis and normal bone 
mineralization, although the mother mice showed severe hypocalcemia (44,45). Thus, it has been 
suggested that the adaptations which occur to meet a substantial calcium demand for fetal bone 
mineralization in pregnancy may occur via a vitamin D-independent route (46).  
However, in contrast to the animal studies, results from human studies are mixed regarding 
the impact of maternal vitamin D status on fetal bone health. Some studies observed associations 
between maternal vitamin D status and indices of bone health in the fetus (e.g., bone mineral 
density and biochemical markers of bone metabolism) (22,47–49), whereas others observed no 
associations (50–52). Moreover, results from a few clinical trials that examined the effect of 
vitamin D supplementation on maternal benefit for bone health among pregnant women did not 
 xxiv 
extend beyond raising serum 25(OH)D concentrations (3,40,53). Nevertheless, the majority of the 
studies did not account for maternal dietary intakes of calcium and phosphorus which could be 
important confounders and contribute to the inconsistencies across study findings. For example, 
low calcium intake can disturb bone metabolism (54) and mask the relationship between vitamin 
D status and bone health. Thus, human feeding studies that control for dietary intakes of 
vitamin D-related nutrients during pregnancy are needed to more precisely assess the 
relationship between maternal vitamin D status and maternal and fetal biomarkers of bone 
metabolism. 
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CHAPTER 1 
Vitamin D metabolism varies among women in different reproductive states consuming the 
same intakes of vitamin D and related nutrients1,2 
 
 
 
 
 
 
 
 
 
1Park H, Brannon PM, West AA, Yan J, Jiang X, Perry CA, Malysheva OV, Mehta S, Caudill MA. 
Vitamin D metabolism varies among women in different reproductive states consuming the same 
intakes of vitamin D and related nutrients. J Nutr. 2016 Aug;146(8):1537-45. doi: 
10.3945/jn.116.229971. Regarding the copyright of this article, authors have the right to include 
the article in their thesis or dissertation. 
2Supported by USDA National Institute of Food and Agriculture, Agriculture and Food Research 
Initiative Education and Literacy Initiative Predoctoral Fellowship 2016-67011-25174; NIH grant 
1R03HD080824-01A1; the Gerber Foundation grant 1843-3882; the American Egg Board/Egg 
Nutrition Center; and the Beef Checkoff, through the National Cattlemen’s Beef Association and 
Nebraska Beef Council. The funding sources had no role in the study design, interpretation of the 
data, and/or publication of results. 
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ABSTRACT 
Background: The impact of the reproductive state on vitamin D metabolism and requirements is 
uncertain in part because of a lack of studies with controlled dietary intakes of vitamin D and 
related nutrients.  
Objective: We aimed to quantify the impact of the reproductive state on a panel of vitamin D 
biomarkers among women of childbearing age consuming equivalent amounts of vitamin D and 
related nutrients.  
Methods: Nested within a feeding study providing 2 doses of choline, healthy pregnant (26–29 
wk gestation; n = 26), lactating (5 wk postpartum; n = 28), and control (nonpregnant/nonlactating; 
n = 21) women consumed a single amount of vitamin D (511±48 IU/d: 311±48 IU/d from diet 
and 200 IU/d as supplemental cholecalciferol) and related nutrients (1.6±0.4 g Ca/d and 1.9±0.3 
g P/d) for 10 wk. Vitamin D biomarkers were measured in blood obtained at baseline and study-
end, and differences in biomarker response among the reproductive groups were assessed with 
linear mixed models adjusted for influential covariates (e.g., body mass index, season, 
race/ethnicity).  
Results: At study-end, pregnant women had higher (P < 0.01) circulating concentrations of 25-
hydroxyvitaminD [25(OH)D; 30%], 1,25-dihydroxyvitamin D [1,25(OH)2D; 80%], vitamin D 
binding protein (67%), and C3 epimer of 25(OH)D3 (100%) than control women. Pregnant women 
also had higher (P < 0.04) ratios of 25(OH)D to 24,25-dihydroxyvitamin D [24,25(OH)2D; 40%] 
and 1,25(OH)2D to 25(OH)D (50%) than control women. In contrast, no differences (P > 0.15) in 
vitamin D biomarkers were detected between the lactating and control groups. Notably, the study 
vitamin D dose of 511 IU/d achieved vitamin D adequacy in most participants (95%) regardless 
of their reproductive state.  
 3 
Conclusions: The higher concentrations of vitamin D biomarkers among pregnant women than 
among control women suggest that metabolic adaptations, likely involving the placenta, transpire 
to enhance vitamin D supply during pregnancy. The study findings also support the adequacy of 
the current vitamin D RDA of 600 IU for achieving serum 25(OH)D concentrations > 50 nmol/L 
among women differing in their reproductive state. This trial was registered at clinicaltrials.gov as 
NCT01127022.  
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INTRODUCTION   
 Worldwide vitamin D inadequacy is common among pregnant and lactating women (1–3), 
and it is linked in some epidemiologic studies to adverse reproductive outcomes, including 
impaired fetal/neonatal growth, preeclampsia, and immune disorders (4, 5). In 2011, the Institute 
of Medicine (IOM) established a vitamin D RDA of 600 IU for women of childbearing age. This 
recommendation was based on the vitamin D intake projected to achieve circulating concentrations 
of 50 nmol/L for 25-hydroxyvitaminD [25(OH)D], the primary indicator of vitamin D status. 
Reproductive state was not considered in the formulation of this RDA because of an absence of 
25(OH)D dose-response data among pregnant and/or lactating women (1, 6). 
 Interestingly, pregnancy is characterized by robust increases in circulating 1,25-
dihydroxyvitamin D [1,25(OH)2D] (7–10), the biologically active form of vitamin D, and vitamin 
D binding protein (DBP) (8, 11, 12), a carrier of vitamin D metabolites in blood. However, the 
effect of pregnancy on circulating 25(OH)D is less clear with studies reporting no effects (7, 11, 
13), increases (9, 14, 15), or decreases (10, 16). These mixed findings across studies may arise 
from intake differences of vitamin D and relevant nutrients (e.g., calcium and phosphorus), which 
were either unknown or incompletely assessed. Some studies have shown that circulating 
concentrations of 1,25(OH)2D, DBP, and 25(OH)D decline during lactation (9, 11, 17, 18); 
however, it is unclear if vitamin D status differs from that of a nonpregnant, nonlactating woman 
under conditions of comparable vitamin D intake. Furthermore, little is known about the effect of 
reproductive state on several additional biomarkers of vitamin D metabolism, including 24,25-
dihydroxyvitamin D [24,25(OH)2D], a catabolite of vitamin D; the ratio of 25(OH)D to 
24,25(OH)2D [25(OH)D:24,25(OH)2D], a newly proposed sensitive indicator of vitamin D status 
(19–22); free 25(OH)D (16, 23); and the C3 epimer of 25-hydroxyvitamin D3 [epi-25(OH)D3], a 
 5 
recently identified metabolite (24, 25) with unknown biological function. 
 To advance understanding of the effects of reproductive state on vitamin D status and 
metabolism, we used samples obtained during a feeding study that provided a single amount of 
vitamin D and related nutrients (e.g., calcium and phosphorus) to pregnant, lactating, and control 
(nonpregnant, nonlactating) women across a 10-wk time period. Our aims were as follows: 1) to 
quantify the impact of reproductive state on a comprehensive panel of blood vitamin D biomarkers; 
2) to examine interrelations among biomarkers of vitamin D metabolism; and 3) to ascertain the 
adequacy of the current RDA for achieving target circulating 25(OH)D concentrations of 50 
nmol/L among pregnant and lactating women. 
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METHODS 
Study participants  
 Pregnant women entering their third trimester (26–29 wk gestation), lactating women (5 
wk postpartum), and control women of reproductive age (nonpregnant and nonlactating) were 
recruited from Ithaca, New York (latitude 42.4˚N) between January 2009 and October 2010 as 
previously described (26, 27). Inclusion criteria included the following: 1) age of 21–40 y; 2) 
healthiness as assessed by health-related questionnaire, a blood chemistry profile, and a complete 
blood count; 3) normal liver and kidney function; 4) willingness to comply with the study protocol; 
5) singleton pregnancy without pregnancy-associated complications (pregnant women only); and 
6) willingness to breastfeed exclusively during the study period (lactating women only). Exclusion 
criteria included use of tobacco, drug, or alcohol and use of prescription medications known to 
affect liver function. The study protocol was reviewed and approved by the Institutional Review 
Board for Human Study Participant Use at Cornell University and the Cayuga Medical Center (the 
hospital where pregnant participants delivered their infants). Informed consent was obtained from 
all study participants before study entry. This trial was registered at clinicaltrials.gov as 
NCT01127022. 
 
Study design, diet, and supplements  
 This study used biological samples obtained during a feeding study in which healthy 
pregnant (n = 26), lactating (n = 28), and control (n = 21) women were randomly assigned to 480 
or 930 mg choline/d for >10 wk (26, 27). Throughout the feeding period, consumption of all 
essential micronutrients was strictly controlled and equivalent across reproductive groups.  
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 A mean total of 511 ± 48 IU vitamin D/d was consumed by participants throughout the 
study period. Of this total, a mean of 311 ± 48 IU vitamin D/d was provided by the 7-d rotational 
menu as estimated with the use of the USDA National Nutrient Database for Standard Reference 
Release 28 (Supplemental Table S1.1), and 200 IU cholecalciferol/d came from a daily prenatal 
multivitamin supplement (Pregnancy Plus; Fairhaven Health LLC). For calcium and phosphorus, 
mean intakes were estimated to be 1.6 ± 0.4 g Ca/d and 1.9 ± 0.3 g P/d (USDA National 
Nutrient Database for Standard Reference Release 28). In addition to the prenatal multivitamin 
supplement, all women consumed a docosahexaenoic acid supplement (200 mg/d; Neuromins; 
Nature’s Way Products) and a potassium and magnesium supplement (3 times/wk; General 
Nutrition Corp). 
 Meals were prepared in the Human Metabolic Research Unit (HMRU) at Cornell 
University. The pregnant and control women consumed > 1 meal/d throughout the week at the 
HMRU, whereas the lactating women consumed 1 meal/d thrice weekly to lessen the burden of 
travel to and from the HMRU while caring for an infant. Supplements were consumed with the 
onsite meal under the supervision of study personnel. All other meals and supplements were 
provided as carry-out and were consumed off site. Participants were required to 1) refrain from 
consuming food, beverages (except water), and supplements outside of those provided by study 
personnel; 2) complete daily checklists of menu items and supplements; and 3) return empty food 
containers and disposables of their carry-out meals and supplements. 
 
Sample collection and processing  
 Fasting (10-h) venous blood samples and 24-h urine samples were obtained at study 
baseline (week 0) and study-end (defined as week 10), processed, and stored at -80˚C (26). 
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Analytical measurements 
25(OH)D. Serum 25(OH)D was quantified with an isotope dilution LC-MS/MS method (24) that 
was validated in part by our laboratory’s achieving the performance target set by the Vitamin D 
External Quality Assessment Scheme for the October 2012 distribution (i.e., within 14% of All 
Laboratory Trimmed Mean; within 4% of the values for Vitamin D External Quality Assessment 
Scheme samples analyzed by the National Institute of Standards and Technology). 25(OH)D was 
extracted from 150-µL serum samples, calibrators, and control samples (24). The calibrators for 
25(OH)D2, 25(OH)D3, and epi-25(OH)D3 were made by diluting ethanol stock solutions with 
PBS-4% albumin. Internal standard (100 µL) that contained 75 nmol d3-25(OH)D3/L and 50 nmol 
d3-25(OH)D2/L (IsoSciences) was then added to all of the samples. Extracts (65 µL) were injected 
onto a PFP column (PFP Accucore 2.1 X 100, 2.6 mm) with matching guard column at 45˚C and 
separated by an LC-MS/MS system that consisted of a Surveyer HPLC system(pump and 
autosampler) and a TSQ Quantum Ultra mass spectrometer operated with XCalibur (2.2 SP1.48) 
software (ThermoElectron Corp). The analytes of interest were eluted from the column at a flow 
rate of 150 µL/min under the following conditions: 73% methanol and 27% water (0–9th min), 
linear gradient from 73% to 100% methanol (9th– 11th min), 100% methanol (11th–12th min), 
linear gradient from 100% to 73% methanol (12th–13th min), and 73% methanol (13th–18th min). 
To prevent deposit build-up in the mass spectrometer, the flow was directed into the spectrometer 
only between the 9th and 16th min. Atmospheric pressure chemical ionization in the positive ion 
mode with the use of selected reaction monitoring was used for detection. Transition pairs for the 
analytes of interest were the same as previously described (24). Intra- and inter-assay CVs were 
2.1% and 4.7%, respectively, from our in-house control duplicates that consisted of 3 human sera 
with 25(OH)D concentrations spanning the range of the calibration curve, a bovine serum rich in 
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25(OH)D2, and National Institute of Standards and Technology SRM 2972 (within the range of 
certified values). We herein refer to the sum of 25(OH)D2 and 25(OH)D3 as “25(OH)D” which 
does not include epi-25(OH)D3. 
 
DBP and 1,25(OH)2D. DBP and 1,25(OH)2D in plasma samples were quantified with ELISA kits 
[R&D Systems for DBP; Immunodiagnostic Systems, Inc. for 1,25(OH)2D], according to the 
manufacturers’ instructions. Intra- and inter-assay CVs for the DBP assays were 5.7% and 5.6%, 
respectively, from our in-house controls of human plasma with 3 different DBP concentrations. In 
the 1,25(OH)2D assays, both intra- and inter-assay CVs were <10% (5.2% and 7.8%, respectively) 
from kit controls of low and high concentrations. In addition, all measured concentrations of the 
kit controls fell within the acceptable ranges provided by the manufacturer. 
 
24,25(OH)2D. Quantification of circulating 24,25(OH)2D was performed with the LC-MS/MS 
method (20) with modifications from our instrumentation. Briefly, 24,25(OH)2D3 calibration 
curves were created by diluting ethanol stock solutions of 24,25(OH)2D3 with PBS-4% albumin. 
All plasma samples, calibrators, and control samples were mixed with 5 µL of internal standard 
solution that contained 1.5 pmol d6-24,25(OH)2D3/L (Toronto Research Chemicals Inc.). Next, 
24,25(OH)2D3 was extracted from 200-µL samples, calibrators, and controls with the use of a 
liquid-liquid extraction, and the upper layer was dried under nitrogen before derivatization with 
DMEQ-TAD (20). Extracts (65 µL) were resuspended in 60:40 methanol/water solution and 
injected onto a PFP column (PFP Accucore 2.1 X 100, 2.6 mm) with matching guard column at 
45˚C and separated by the LC-MS/MS system described for serum 25(OH)D quantification. 
24,25(OH)2D3 was eluted from the column at a flow rate of 200 µL/min under the following 
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conditions: 40% acetonitrile and 60% water (0–3rd min), linear gradient from 40% to 60% 
acetonitrile (3rd–5th min), 60% acetonitrile (5th–10th min), linear gradient from 50% to 70% 
acetonitrile (10th–12th min), linear gradient 70–80% acetonitrile (12th–15th min), returning to 
40% acetonitrile (15th–17th min). To prevent deposit build-up, the flow directed into the mass 
spectrometer was limited from the 2nd to 10th min. Atmospheric pressure chemical ionization in 
the positive ion mode with selected reaction monitoring was used for 24,25(OH)2D3 detection. 
Two transition pairs were used for 24,25(OH)2D3 [m/z 762.5 > 468.2 (762.5 > 247.1 qualifier)], 
whereas a single transition pair was used for d6-24,25(OH)2D3 (m/z 768.5 > 247.1). Intra- and 
inter-assay CVs were 5.7% and 4.9%, respectively, from duplicate measurements of our in-house 
control samples (human plasma with 2 different 24,25(OH)2D3 concentrations). 
 
Free 25(OH)D. Free 25(OH)D concentrations were estimated with a previously described 
equation (28, 29) in which quantified circulating concentrations of 25(OH)D [i.e., 25(OH)D2 and 
25(OH)D3], albumin, and DBP were computed. Because of limited availability of serum samples, 
plasma DBP concentrations were measured and then entered in the equation. 
 
Total calcium. Serum total calcium was quantified by an automated chemistry analyzer 
(Dimension Xpand Plus; Siemens Healthcare Diagnostics). 
 
Genotyping. The GC (vitamin D binding protein gene) rs7041 G > T, CYP2R1 (25-hydroxylase 
gene) rs12794714 A > G, and CYP2R1 rs10741657 A > G genotypes were determined by Endpoint 
Genotyping on a Roche LightCycler 480 with the use of the Applied Biosystems TaqMan 
Genotyping Assays (Life Technologies) after DNA extraction and purification with the Qiagen 
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DNeasy kit. 
 
Statistical analysis  
 To test for differences in baseline characteristics among the reproductive groups, we used 
1-factor ANOVA for normally distributed continuous variables, Kruskal-Wallis test for non-
normally distributed continuous variables, and χ2 tests or Fisher exact tests for categorical 
variables. To examine the effect of reproductive state on biomarkers of vitamin D metabolism at 
both study baseline and study-end, we used linear mixed-effects models (LMMs). For each 
biomarker, the LMM included reproductive state, time, and their interaction term as fixed effects, 
and a random participant identifier factor. In addition, each LMM considered the following 
covariates: age, ethnicity/race, prepregnancy/baseline BMI (in kg/m2), education, season of study 
entry, multivitamin supplement use before study entry, genetic variants in vitamin D metabolism, 
and choline intake (480 or 930 mg/d). Covariates that achieved statistical significance (P < 0.05) 
were retained in the final models, and the Bonferroni correction was used for post hoc 
comparisons. Finally, relations among the biomarkers of vitamin D were assessed with Pearson 
correlation analysis.  
 All analyses were performed with JMP Pro 11 (SAS Institute, Inc.). Data that did not meet 
the normality and homogeneity of variance criteria were ln-transformed. Two influential outliers 
with studentized residuals >3 were excluded from free 25(OH)D analysis. Because epi- 25(OH)D3 
had values below the limit of detection of 1.0 nmol/L, the limit of detection was used in place of 
“not detectable” among 47% of control, 31% of pregnant, and 54% of lactating women in the 
statistical models. Data are presented as arithmetic means ± SDs or geometric means (95% CI), 
unless otherwise specified. P values were 2-tailed and considered significant at <0.05. Data 
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derived from the LMMs are “predicted mean concentrations (or ratios)” of the vitamin D 
biomarkers and account for influential covariates. 
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RESULTS 
Participant characteristics and study baseline measurements (ANOVA)  
 The characteristics of the study participants (26 pregnant, 28 lactating, and 21 control 
women) and their study baseline (week 0) measures are shown in Table 1.1. No differences in age 
and prepregnancy/baseline BMI were observed among the reproductive groups. In addition, the 
distributions of ethnicity/race, season of study entry, and education were balanced across the 
groups as were the distributions of the vitamin D-related genetic variants, GC rs7041 G>T and 
CYP2R1 rs12794714 A>G polymorphisms. In contrast, CYP2R1 rs10741657 A>G polymorphism 
distribution differed (P = 0.03) among the groups with the pregnant women having a lower 
prevalence of the variant GG genotype than the control and lactating women. Multivitamin 
supplement use before study entry also differed (P < 0.001) among the reproductive groups, with 
higher use in the pregnant and lactating women than in the control women.  
 Most vitamin D metabolites varied by reproductive state at baseline (Table 1.1). The 
pregnant women exhibited 40% higher (P = 0.01) serum 25(OH)D concentrations than the control 
women, and 100–150% higher (P < 0.001) DBP concentrations than the control and lactating 
women. Similarly, the pregnant women had 90% and 130% higher (P < 0.001) 1,25(OH)2D 
concentrations than the control and lactating women, respectively. Although 24,25(OH)2D 
concentrations did not differ across the groups at baseline, 25(OH)D:24,25(OH)2D was higher in 
the pregnant women than in the control (30%; P = 0.03) and lactating (61%; P < 0.001) women, 
which did not differ from each other. The pregnant women also had 70% higher (P = 0.048) serum 
epi-25(OH)D3 concentrations than those of the control women and almost double (P = 0.004) the 
concentrations of the lactating women. 
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 The lactating women differed from the control and pregnant women in several variables. 
The 1,25(OH)2D:25(OH)D was lower in the lactating women than in the control (-31%; P = 0.04) 
and pregnant (-47%; P < 0.001) women, which did not differ from each other. In addition, the 
lactating women showed higher concentrations of free 25(OH)D than the control (47%; P = 0.03) 
and pregnant (67%; P = 0.002) women, which did not differ from each other. Finally, the lactating 
women had higher (P < 0.03) serum calcium concentrations than the control and pregnant women, 
which differed from each other with lower (P < 0.001) serum calcium concentrations among the 
pregnant women. 
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Table 1.1 
Baseline characteristics and concentrations of vitamin D metabolites 
among the pregnant, lactating, and control women1 
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Pregnant (n=26) Lactating (n=28) Control (n=21) P 
Age, y 28 ± 3 29 ± 5 29 ± 5 0.82 
Ethnicity, n 0.81 
    White    16 20 14  
    African American 1 1 2  
    Hispanic 4 3 2  
    Asian 4 1 1  
    Other 1 3 2  
BMI2, kg/m2 23 [21, 26] 25 [21, 32] 24 [21, 25] 0.45 
Season at study-entry, n  0.81 
    April–September    14 17 11  
    October–March    12 11 10  
Multivitamin supplement use   <0.001 
before study-entry, n  22 21  7   
Education, n  0.30 
   < High school     4 8 6  
   College  11 13 5  
   > College  11 17 10  
GC rs7041 G>T polymorphism, n  0.35 
    GG  9 3 6  
    GT   11 16 9  
    TT 6 8 6  
CYP2R1 rs10741657 A>G polymorphism, n  0.03 
    AA  2 3 2  
    AG 20 12 8  
    GG 4 13 11  
CYP2R1 rs12794714 A>G polymorphism, n  0.15 
    AA  5 9 6  
    AG 20 13 11  
    GG 1 6 4  
Serum 25(OH)D, nmol/L 89 ± 29a 73 ± 23ab 64 ± 25b 0.006 
Plasma DBP, μg/mL 405 (319, 515)a 165 (136, 199)b 204 (164, 254)b <0.001 
Plasma 1,25(OH)2D, pmol/L 283 (232, 344)
a 125 (104, 152)b 151 (129, 178)b <0.001 
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Table 1.1 (Continued) 
 
    
Plasma 24,25(OH)2D, nmol/L 9.6 (7.5, 12.4) 12.7 (10.2, 15.9) 9.1 (6.7, 12.5) 0.13 
25(OH)D: 24,25(OH)2D  8.7 (7.5, 10.1)
a 5.4 (4.8, 6.1)b 6.7 (5.8, 7.8)b <0.001 
1,25(OH)2D: 25(OH)D  3.4 (2.7, 4.2)
a 1.8 (1.5, 2.2)b 2.6 (2.1, 3.2)a <0.001 
Serum epi-25(OH)D3, nmol/L 3.2 ± 2.1
a 1.5 ± 0.9b 1.9 ± 1.2b 0.003 
Free 25(OH)D, pmol/L 17.3 (13.8, 21.5)b 28.8 (24.1, 34.4)a 19.5 (14.9, 25.5)b 0.002 
Serum total calcium, mg/dL 8.7 ± 0.4c 9.4 ± 0.3a 9.2 ± 0.3b <0.001 
 
1 Values are geometric means (95% CIs), means±SDs, or medians [IQRs]. Values in a row with 
a superscript letter indicate significant differences in the vitamin D metabolite among the 
reproductive groups (i.e., a>b>c), P < 0.05. CYP2R1, 25-hydroxylase gene; DBP, vitamin D 
binding protein; epi-25(OH)D3, C3 epimer of 25-hydroxyvitamin D3; GC, vitamin D binding 
protein gene; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 1,25(OH)2D:25(OH)D, ratio of 1,25-
dihydroxyvitamin D to 25-hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; 
25(OH)D, 25-hydroxyvitamin D; 25(OH)D:24,25(OH)2D, ratio of 25-hydroxyvitamin D to 24,25-
dihydroxyvitamin D.  
2 Self-reported prepregnancy BMI of the pregnant and lactating women and baseline BMI of the 
control women. 
 
 
Effect of reproductive state on blood biomarkers of vitamin D metabolism (covariate-
adjusted LMM)  
Serum 25(OH)D. Reproductive state did not interact with time (P = 0.48) to affect serum 25(OH)D 
concentrations. However, a 25% increase (P = 0.02) in 25(OH)D concentrations was observed 
among the control women but not among the pregnant and lactating women whose concentrations 
remained stable (P > 0.21) throughout the study (Figure 1.1A). Similar to study baseline, the 
pregnant women had ~30% higher (P <0.01) concentrations of 25(OH)D (89 nmol/L) than the 
control women (69 nmol/L) at study-end (Figure 1.1A), whereas serum 25(OH)D concentrations 
in the lactating women (75 nmol/L) did not differ (P > 0.15) from the pregnant and control women. 
At study-end, predicted mean serum concentrations for all reproductive groups were above the 
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estimated average requirement and RDA target values of 40 nmol/L and 50 nmol/L, respectively 
(Figure 1.1A). In addition, all participants, except for 2 pregnant and 2 control women, had 
unadjusted 25(OH)D concentrations > 50 nmol/L. 
 
Plasma DBP. Reproductive state did not interact with time (P = 0.13) to influence circulating DBP 
concentrations that did not change (P > 0.9) among the lactating and control women but tended to 
decrease (-9%; P = 0.07) among the pregnant women (Figure 1.1B). Similar to study baseline, the 
pregnant women had 67% higher (P < 0.001) DBP concentrations (340 µg/mL) than the control 
women (203 µg/mL) and almost 100% higher (P < 0.001) concentrations than the lactating women 
(173 µg/mL) at study-end. DBP concentrations in the lactating and control women did not differ 
(P = 0.42) from each other (Figure 1.1B). 
 
Plasma 1,25(OH)2D. Reproductive state did not interact with time (P = 0.88) to affect circulating 
1,25(OH)2D response with stable (P > 0.52) concentrations of 1,25(OH)2D among all the 
reproductive groups throughout the study (Figure 1.1C). Similar to study baseline, the pregnant 
women had 80% and 120% higher (P < 0.001) 1,25(OH)2D concentrations (299 pmol/L) than the 
control (162 pmol/L) and lactating (134 pmol/L) women at study-end, respectively (Figure 1.1C). 
1,25(OH)2D concentrations in the lactating and control women did not differ from each other (P > 
0.9). 
 
Plasma 24,25(OH)2D. Reproductive state interacted with time (P = 0.003) to affect circulating 
24,25(OH)2D concentrations. Although no changes (P > 0.31) in 24,25(OH)2D concentrations 
were observed within the pregnant and lactating women throughout the study, 24,25(OH)2D 
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tended to increase (22%; P =0.06) among the control women (Figure 1.1D). Interestingly, despite 
42% higher (P < 0.03) concentrations of 24,25(OH)2D in the lactating women than the pregnant 
women at baseline, no differences (P > 0.9) were detected among the pregnant (8.3 nmol/L), 
lactating (8.5 nmol/L), and control (9.8 nmol/L) groups at study-end (Figure 1.1D). 
 
25(OH)D:24,25(OH)2D. Reproductive state and time interacted (P < 0.001) to influence 
25(OH)D:24,25(OH)2D, with increases (P < 0.001) observed among the lactating women (Figure 
1.1E) but not among the pregnant and control women (P > 0.9). Similar to study baseline, the 
pregnant women exhibited a 40% higher ratio (P < 0.001) than the control women (8.8 compared 
with 6.3) at study-end. However, in contrast to the higher ratio (P < 0.001) among the pregnant 
(compared with lactating) women at study baseline, no difference (P = 0.17) between the 2 groups 
(8.8 compared with 7.4) was detected at study-end (Figure 1.1E). 
 
1,25(OH)2D:25(OH)D. Reproductive state did not interact with time (P = 0.36) to influence 
1,25(OH)2D:25(OH)D that remained stable (P > 0.56) among all the reproductive groups across 
study time points. At study-end, the pregnant women had a 50% higher ratio (P = 0.04) than the 
control women (3.3 compared with 2.2), despite no differences (P = 0.53) in this ratio between the 
2 groups at study baseline (Figure 1.1F). The pregnant women also had an 83% higher (P < 0.001) 
1,25(OH)2D:25(OH)D than the lactating women (3.3 compared with 1.8) at study-end, which was 
similar to study baseline (Figure 1.1F). 
 
Serum epi-25(OH)D3. Reproductive state did not interact with time (P = 0.92) to influence serum 
epi-25(OH)D3 concentrations that did not change (P > 0.9) among all reproductive states 
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throughout the study. Similar to study baseline, epi-25(OH)D3 concentrations in the pregnant 
group (3.05 nmol/L) were twice (P < 0.004) those of the control (1.51 nmol/L) and lactating (1.31 
nmol/L) groups at study-end (Figure 1.1G), which did not differ from each other (P > 0.9). 
 
Free 25(OH)D. Reproductive state did not interact with time (P = 0.65) to affect free 25(OH)D 
concentrations that remained stable (P > 0.1) among the lactating and control women over the 
course of the study and increased slightly (10%; P = 0.02) among the pregnant women (Figure 
1.1H). Although the lactating women tended to have higher (P = 0.05) concentrations of free 
25(OH)D than the control women at study baseline, no difference (P = 0.15) was observed among 
these groups at study-end (31.3 and 24.1 pmol/L for lactating and control women, respectively). 
Similar to study baseline, the lactating women had 66% higher (P < 0.001) concentrations of free 
25(OH)D than those of the pregnant women (18.8 pmol/L) at study-end, which did not differ from 
the control women (P = 0.18). 
 
Serum total calcium. Reproductive state did not interact with time (P = 0.46) to influence serum 
calcium concentrations that was stable (P > 0.5) among the lactating and control women but 
increased slightly (3%; P = 0.04) in the pregnant women throughout the study (Figure 1.1I). 
Similar to study baseline, the lactating women (9.6 mg/dL) had higher calcium concentrations than 
those of the control (9.2 mg/dL; P = 0.003) and pregnant women (8.9 mg/dL; P < 0.001) at study-
end. In addition, the pregnant women showed lower (P = 0.01) serum calcium concentrations than 
the control women at study-end.
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Figure 1.1. Circulating vitamin D metabolites [25(OH)D (A), DBP (B), 1,25(OH)2D (C), 
24,25(OH)2D (D), 25(OH)D:24,25(OH)2D (E), 1,25(OH)2D:25(OH)D (F), epi-25(OH)D3 (G), 
free 25(OH)D (H), and total calcium (I)] among the pregnant (n = 26), lactating (n = 28), and 
control (n = 21) women who consumed equivalent amounts of vitamin D and related nutrients 
(e.g., calcium and phosphorus) for 10 wk. All concentrations are predicted geometric means (95% 
CIs), except 25(OH)D (predicted arithmetic mean), derived from the covariate-adjusted linear 
mixed models. Means at a time without a common letter differ, P < 0.05. *,† Significantly different 
from baseline: *P < 0.05; †P < 0.07. DBP, vitamin D binding protein; epi-25(OH)D3, C3 epimer 
of 25-hydroxyvitamin D3; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 1,25(OH)2D:25(OH)D, ratio of 
1,25-dihydroxyvitamin D to 25-hydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; 
25(OH)D, 25-hydroxyvitamin D; 25(OH)D:24,25(OH)2D, ratio of 25-hydroxyvitamin D to 24,25-
dihydroxyvitamin D. 
 
 
Associations among circulating vitamin D metabolites in all participants throughout the 
study  
 Among all study participants, circulating 25(OH)D correlated positively with 
24,25(OH)2D (Figure 1.2A), 1,25(OH)2D (Figure 1.2B), DBP (Figure 1.2C), and free 25(OH)D 
(Figure 1.2D) at both baseline and study-end. 1,25(OH)2D and 24,25(OH)2D were correlated 
throughout the study (Figure 1.2E) as was 1,25(OH)2D with DBP (Figure 1.2F). No correlations 
were detected between 1,25(OH)2D and free 25(OH)D at either baseline (P = 0.68) or study-end 
(P = 0.29); however, free 25(OH)D correlated positively with 24,25(OH)2D at both study time 
points (Figure 1.2G). 
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Figure 1.2. Relations among circulating vitamin D metabolites in all participants (n = 75) by study 
time point: 25(OH)D and 24,25(OH)2D (A), 25(OH)D and 1,25(OH)2D (B), 25(OH)D and DBP 
(C), free 25(OH)D and 25(OH)D (D), 1,25(OH)2D and 24,25(OH)2D (E), 1,25(OH)2D and DBP 
(F), and free 25(OH)D and 24,25(OH)2D (G). All metabolites were ln-transformed, except for 
25(OH)D. DBP, vitamin D binding protein; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 24,25(OH)2D, 
24,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D. 
 
 
Associations among circulating vitamin D metabolites by reproductive state at study-end  
 At study-end, circulating 25(OH)D correlated positively with 1,25(OH)2D among the 
control women (Table 1.2) and tended to correlate among the pregnant women (r = 0.36, P = 
0.07). 25(OH)D was also highly correlated with 24,25(OH)2D, and with epi-25(OH)D3 in all the 
reproductive groups (Table 1.2). Although 1,25(OH)2D correlated positively with 24,25(OH)2D 
among the control women, no relation between these metabolites was observed among the 
pregnant or lactating women.  
 Epi-25(OH)D3 correlated positively with 24,25(OH)2D in all the reproductive groups and 
with DBP in the pregnant women at study-end (Table 1.2). In addition, free 25(OH)D correlated 
with epi-25(OH)D3 and with 24,25(OH)2D among the pregnant and control women at study-end 
(Table 1.2). However, only the pregnant women showed correlations of free 25(OH)D with 
25(OH)D (r = 0.38, P = 0.057) and 1,25(OH)2D (Table 1.2). 
 
 
 
 
 
 
 25 
 
 
 
 
Table 1.2. Correlations among circulating vitamin D metabolites in pregnant, lactating and control 
women at study-end1 
 
Correlations between 
Pregnant  
(n = 26)  
Lactating  
(n = 28)  
Control  
(n = 21)  
vitamin D metabolites r P r P r P 
25(OH)D,  1,25(OH)2D - NS - NS 0.48 0.03  
25(OH)D,  24,25(OH)2D 0.85 <0.001  0.67 <0.001  0.89 <0.001  
25(OH)D,  DBP - NS - NS - NS 
25(OH)D,  Epi-25(OH)D3 0.72 <0.001 0.63 <0.001 0.59 0.007 
25(OH)D,  Free 25(OH)D - NS - NS - NS 
1,25(OH)2D,  24,25(OH)2D - NS - NS 0.64 0.002 
1,25(OH)2D,  DBP - NS - NS - NS 
1,25(OH)2D,  Free 25(OH)D 0.47 0.02 - NS - NS 
1,25(OH)2D,  Epi-25(OH)D3 - NS - NS - NS 
Free 25(OH)D,  24,25(OH)2D 0.46 0.02 - NS 0.48 0.03 
Free 25(OH)D,  Epi-25(OH)D3 0.49 0.03 - NS 0.42 0.03 
Epi-25(OH)D3,  DBP 0.40 0.04 - NS - NS 
Epi-25(OH)D3,  24,25(OH)2D 0.56 0.003 0.58 0.001 0.49 0.03 
 
1 Metabolites were ln-transformed, except 25(OH)D and epi-25(OH)D3. NS, P > 0.05. DBP, 
vitamin D binding protein; epi-25(OH)D3, C3 epimer of 25-hydroxyvitamin D3; 1,25(OH)2D, 
1,25-dihydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D; 25(OH)D, 25-
hydroxyvitamin D. 
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DISCUSSION 
 To the best of our knowledge, this is the first feeding study to control intakes of vitamin D 
and related nutrients such as calcium and phosphorus that can affect vitamin D status and 
metabolism. Three main findings emerged as follows: 1) pregnancy induces alterations in vitamin 
D metabolism, including increases in 25(OH)D, 25(OH)D:24,25(OH)2D, and epi-25(OH)D3; 2) 
reproductive state modulates the interrelations among circulating vitamin D metabolites; and 3) 
the RDA for vitamin D is likely adequate for most women of reproductive age, including pregnant 
and lactating women. 
 
Pregnancy increases the circulating pool of vitamin D 
 Circulating concentrations of 1,25(OH)2D, DBP, and 1,25(OH)2D:25(OH)D were 
significantly higher among third-trimester pregnant women than the control women, confirming 
previous reports (7–12). The pregnant women also exhibited significantly higher circulating 
concentrations of 25(OH)D than the control women even after adjusting for season, prestudy 
supplement use, ethnicity/race, BMI, and genetic variants that influence 25(OH)D concentrations. 
This elevation in 25(OH)D paralleled the rise in DBP among the pregnant women, suggesting that 
DBP-bound 25(OH)D, rather than free 25(OH)D (which did not differ between the pregnant and 
control women), contributed to the higher total circulating concentrations of this metabolite. DBP-
bound 25(OH)D may be favored over the free form because it is more stable and is taken up in a 
regulated manner by tissues that express megalin-cubilin receptors such as the placenta (30).  
 No differences in circulating concentrations of 24,25(OH)2D, a major catabolite of 
25(OH)D (22), were detected between the pregnant and control women. However, 
25(OH)D:24,25(OH)2D was significantly higher among the pregnant women than the control 
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women, indicating attenuation of vitamin D catabolism in this reproductive state. In addition, the 
pregnant women had higher concentrations of epi-25(OH)D3 than the control women which may 
be a consequence of the elevated maternal vitamin D pool or could imply a possible role for this 
metabolite in maternal and fetal health.  
 In contrast to the robust effects of pregnancy on biomarkers of vitamin D metabolism, no 
differences were detected at study-end between the lactating (15 wk postpartum) and control 
women. These findings are consistent with previous reports that examined calcium homeostasis 
during lactation (9, 11, 31). Of note, circulating 25(OH)D:24,25(OH)2D increased throughout the 
study among lactating women because of a decrease in their 24,25(OH)2D. Thus, lactating women 
may achieve vitamin D pools that are similar to nonlactating women by reducing 24-hydoxylase 
(CYP24A1) activity. 
 
Reproductive state influenced the interrelations among circulating vitamin D metabolites 
 Data from the present study showed strong positive correlations between 25(OH)D and 
24,25(OH)2D at study-end among the pregnant, lactating, and control women, supporting the 
catabolism of 25(OH)D to 24,25(OH)2D as a means to maintain homeostasis. These findings are 
consistent with previous reports in healthy adults (19, 20, 22) and pregnant women at term (7), but 
they deviate somewhat from a study in lactating women which reported significant correlations of 
25(OH)D and 24,25(OH)2D at 1 wk postpartum but not at later time points (18). In addition, 
although 25(OH)D tended (n = 26; r = 0.36; P = 0.07) to be correlated with the bioactive 
1,25(OH)2D metabolite among the pregnant women at study-end, the linear relation between these 
2 metabolites became significant when the pregnant women with serum 25(OH)D concentrations 
< 100 nmol/L were examined separately (n =33; r =0.39; P = 0.02). This finding supports prior 
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work to suggest that substrate-dependent 1,25(OH)2D production from 25(OH)D reaches a plateau 
at ~100 nmol 25(OH)D/L in pregnant women (32). Pregnant women also exhibited a higher 
number of significant correlations between free 25(OH)D, a metabolite recently linked to bone 
health (33, 34), and other metabolites. Specifically, free 25(OH)D was associated with 4 
metabolites among pregnant women [i.e., total 25(OH)D, 1,25(OH)2D, 24,25(OH)2D, and epi-
25(OH)D3], 2 metabolites among control women [i.e., 24,25(OH)2D and epi-25(OH)D3], and zero 
metabolites among lactating women. This suggests that free 25(OH)D may be a useful indicator 
of vitamin D status during pregnancy but not during lactation. Notably, the bioactive metabolite 
1,25(OH)2D, was associated with 24,25(OH)2D concentrations in control women but not in 
pregnant and lactating women. This finding supports the notion that feedback inhibition of 
1,25(OH)2D production (by CYP24A1) is uncoupled during pregnancy (35, 36) and lactation, 
possibly because of a higher demand for 1,25(OH)2D in these reproductive states. 
 
Vitamin D intake approximating the current RDA achieved adequacy in >90% of the study 
participants within each reproductive group 
 This study provided a mean of 511 IU vitamin D/d, falling between the current estimated 
average requirement (400 IU/d) and the RDA (600 IU/d), through a mixed diet and a prenatal 
supplement. Although a simulated dose-response curve of serum 25(OH)D concentrations 
generated by the IOM did not include pregnant and lactating populations (6), it is notable that the 
study dose readily achieved 25(OH)D concentrations above both the RDA-targeted value and the 
IOM cutoff for vitamin D adequacy (>50 nmol/L) in 95% of the participants: 92% in pregnant, 
100% in lactating, and 90% in control women after a 10-wk period of controlled feeding. In 
addition, on examining 25(OH)D:24,25(OH)2D, all participants had values <20 (unadjusted ratios) 
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at study-end, corresponding to vitamin D sufficiency (20). As such, the RDA of 600 IU/d, which 
is higher than the vitamin D dose of the present study, would be expected to meet vitamin D 
requirements of these populations as defined by the IOM (5), although additional dose-response 
studies are warranted. 
 
Study limitations 
 The provision of a single dose of vitamin D is the main limitation of this study. We cannot 
exclude the possibility that the effect of reproductive state on vitamin D biomarkers and their 
relations might differ under conditions of lower or higher vitamin D intakes. In addition, oral 
contraceptive use of the control women was not considered in our statistical models. However, 
inclusion of this variable would be expected to accentuate the difference between the pregnant and 
control women (8 of whom used oral contraceptives), secondary to the positive relation between 
oral contraceptive use and serum 25(OH)D concentrations (37). 
 
Conclusions 
 Pregnancy increases circulating pools of vitamin D metabolites in a manner that is 
independent of dietary intake, supplement use, season, ethnicity/race, and BMI. The factors 
contributing to this increase are unclear, but they may involve the placenta that expresses the 
vitamin D machinery required for the synthesis of 25(OH)D and 1,25(OH)2D (30, 38, 39). The 
study findings also show that interrelations among vitamin D metabolites are modified by 
reproductive state, particularly during pregnancy. Finally, our data support the adequacy of the 
vitamin D RDA (600 IU) for achieving serum 25(OH)D concentrations of 50 nmol/L among 
women of childbearing age, including those who are pregnant or breastfeeding. 
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Supplemental Table S1.1  
Daily estimated intakes of vitamin D provided by the 7-day rotational menu1,2
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Day Breakfast and Snack Lunch Dinner 
Vitamin D 
Intake (IU) 
 
Monday 
 
 
 
 
 
 
 
2 eggs, scrambled (72) 
2 slices WW3 toast (0) 
1 fruit cup (peaches; 0) 
Fruit juice4 (0) 
Yogurt5 (85)  
V8 juice6 (0) 
 
Pesto sandwich: 
    2 slices WW bread (0) 
    Pesto (0) 
    Swiss Cheese (8.9) 
    Romaine lettuce (0) 
Celery sticks (0) 
Carrot sticks (0) 
 
Beef & cheese tacos: 
    3 corn tortillas (0) 
    Ground beef (80% lean;  
    8.6) 
    Cheddar cheese (7.4) 
    Iceberg lettuce (0) 
Melon (0) 
Milk7 (135) 
 
317  
 
Tuesday 
 
 
 
 
 
 
 
Waffle (0) 
1 egg, hard-boiled (44) 
Fruit juice (0) 
Yogurt (85)  
V8 juice (0) 
 
Tuna sandwich: 
    2 slices WW bread (0) 
    Tuna, canned (light;                
    102) 
    Cheddar Cheese (7.4) 
    Iceberg lettuce (0) 
    Mayonnaise (1.1) 
Grapes (0) 
 
Spaghetti: 
    Cooked pasta (0) 
    Tomato sauce (0) 
    Mushrooms (white; 2.1) 
    Parmesan cheese (2.0) 
    Mozzarella cheese (3.5) 
Milk (135) 
 
329  
 
Wednesday 
 
 
 
 
 
 
 
 
Fitness Crunch cereal (0) 
Milk (135) 
1 box of raisins (0) 
1 medium banana (0) 
Fruit juice (0) 
Yogurt (85)  
V8 juice (0) 
 
Pastrami sandwich: 
    2 slices WW bread (0) 
    Pastrami (1.0) 
    Swiss cheese (4.9) 
    Romaine lettuce (0) 
Cucumber (0) 
 
Vegetarian pizza: 
    Dough (0) 
    Tomato sauce (0) 
    Red peppers, jarred (0) 
    Mushrooms (white; 2.1) 
    Spinach (0) 
    Mozzarella cheese (3.5) 
Apple sauce (0) 
Milk (135) 
 
370 
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Supplemental Table S1.1 (Continued) 
 
Day Breakfast and Snack Lunch Dinner 
Vitamin D 
Intake (IU) 
 
Thursday 
 
 
 
 
 
 
2 pancakes (0) 
Blueberries, frozen (0) 
Fruit juice (0) 
Yogurt (85)  
V8 juice (0) 
 
Egg salad sandwich: 
    2 slices WW bread (0) 
    1 egg, hard-boiled (44) 
    Mayonnaise (1.4) 
    Romaine lettuce (0)  
Celery sticks (0) 
Carrot sticks (0) 
 
Beef & broccoli stir-fry: 
    Beef (sirloin steak; 4.2) 
    Broccoli, frozen (0) 
    Rice (0) 
    Onions, frozen (0) 
Melon (0) 
Milk (135) 
 
268 
 
Friday 
 
 
 
 
 
 
 
 
 
1 WW bagel (0) 
1 fruit cup (oranges; 0) 
Fruit juice (0) 
Yogurt (85)  
V8 juice (0) 
 
Bean Burrito: 
    Black beans, canned (0) 
    Cheddar cheese (7.4) 
    Rice (0) 
    1 large WW tortilla (0) 
 
Lasagna: 
    2 WW lasagna noodles,   
    dry (0) 
    Tomato sauce (0) 
    Ground beef (80% lean;  
    4.9) 
    Cottage cheese (0) 
    Mozzarella cheese (3.5) 
    Parmesan cheese (2.0) 
    Summer squash (0) 
    Zucchini (0) 
Milk (135) 
 
238 
 
Saturday 
 
 
 
 
 
 
2 raspberry muffins (4.2) 
1 medium banana (0) 
Fruit juice (0) 
Yogurt (85)  
V8 juice (0) 
 
Turkey Sandwich: 
    2 slices WW bread (0)   
    Turkey (breast; 2.1) 
    Provolone cheese (4.9) 
    Iceberg lettuce (0) 
Cucumber (0) 
 
Chicken Quesadilla: 
    Chicken (breast; 3.0) 
    2 large WW tortillas (0) 
    Cheddar cheese (37) 
    Corn, frozen (0) 
Milk (135) 
 
296 
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Supplemental Table S1.1 (Continued) 
 
Day Breakfast and Snack Lunch Dinner 
Vitamin D 
Intake (IU) 
 
Sunday 
 
 
 
 
 
 
 
 
Oat granola cereal (0) 
Milk (135) 
1 box of raisins (0) 
1 fruit cup (peaches; 0) 
Fruit juice (0) 
Yogurt (85)  
V8 juice (0) 
 
Vegetable soup (0) 
Corn muffin (0) 
Grapes (0) 
 
Goulash: 
    Cooked pasta (0) 
    Beef (sirloin steak; 4.2) 
    Onion, frozen (0) 
    Red peppers, jarred (0) 
    Tomatoes, canned (0) 
    Tomato puree (0) 
    Potatoes, canned (0) 
Pineapple, canned (0) 
Milk (135) 
 
360 
 
1 Vitamin D intake levels were estimated using the USDA National Nutrient Database for Standard Reference (ref 28). 
2 Values in the parentheses represent amount of vitamin D in international units. 
3 WW, whole wheat 
4 Apple, cranberry-grape, or cranberry juice  
5 Yogurt (vitamin D fortified; raspberry, peach, or vanilla flavored; Dannon Company)  
6 V8 juice (Campbell Soup Company)  
7 Fluid milk (vitamin D fortified; whole, reduced fat, non-fat, or chocolate milk; Cornell Dairy products)  
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CHAPTER 2 
Placental vitamin D metabolism and its associations with circulating vitamin D metabolites  
in pregnant women1,2  
 
 
 
 
 
 
 
 
 
 
 
 
1Park H, Wood M, Malysheva OV, Jones S, Mehta S, Brannon PM, Caudill MA. 
This paper will be submitted for publication within the next few months.  
2Supported by USDA National Institute of Food and Agriculture, Agriculture and Food Research 
Initiative Education and Literacy Initiative Predoctoral Fellowship 2016-67011-25174; NIH grant 
1R03HD080824-01A1; the Gerber Foundation grant 1843-3882; the American Egg Board/Egg 
Nutrition Center; and the Beef Checkoff, through the National Cattlemen’s Beef Association and 
Nebraska Beef Council. The funding sources had no role in the study design, interpretation of the 
data, and/or publication of results. 
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ABSTRACT 
Context: Little is known about placental vitamin D metabolism and its impact on the maternal 
compartment.   
Objective: This study sought to advance understanding of placental vitamin D metabolism and its 
role in modulating maternal circulating vitamin D metabolites.  
Design, Setting, and Participants: Nested within a feeding study, 24 pregnant women consumed 
a single amount of vitamin D (511IU/d) for 10 weeks and provided blood and placental tissue for 
vitamin D biomarker assessment. In addition, cultured human trophoblasts were incubated with 
13C-vitamin D3 to examine intracellular generation of vitamin D metabolites and their secretion.     
Main Outcomes: Placental and circulating vitamin D metabolites; placental mRNA abundance of 
vitamin D metabolic components; trophoblast 13C-labeled vitamin D metabolites and mRNA 
abundance.  
Results: In placental tissue, 25(OH)D3 was strongly correlated (r=0.83, P<0.001) with 
24,25(OH)2D3.  Moreover, these placental metabolites were strongly correlated (r<0.85, P<0.04) 
with their respective metabolites in maternal circulation. Positive associations (P<0.03) were also 
observed between placental mRNA abundance of vitamin D metabolic machinery and circulating 
vitamin D metabolites (i.e., LRP2 with 25(OH)D3 and epi-25(OH)D3; CUBN with 25(OH)D3; 
CYP2R1 with epi-25(OH)D3; CYP24A1 with 25(OH)D3, 24,25(OH)2D3, epi-25(OH)D3 and 
1,25(OH)2D3; CYP27B1 with epi-25(OH)D3 and 1,25(OH)2D3. Remarkably, trophoblasts 
incubated with 13C-vitamin D3 showed 
13C-25(OH)D3 production and secretion, and CYP24A1 
transcript induction in vitro.   
Conclusions: The significant associations between many of the placental biomarkers of vitamin 
D metabolism and circulating vitamin D metabolites among pregnant women, along with evidence 
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of trophoblast production and secretion of vitamin D metabolites, especially 25(OH)D3, suggest 
that the placenta modulates the vitamin D metabolite profile in maternal circulation. 
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INTRODUCTION 
Substantial alterations in circulating concentrations of vitamin D metabolites and related 
proteins have been observed during human pregnancy. For example, circulating concentrations of 
1,25-dihydroxyvitamin D3 [1,25(OH)2D3], a bioactive vitamin D metabolite, and vitamin D 
binding protein (DBP), a carrier for circulating vitamin D metabolites, have been shown to increase 
by 1.5-2.0 times across gestation (1–4). Similarly, increases in 25-hydroxyvitamin D3 [25(OH)D3] 
(2,5,6), the major form of vitamin D in blood, and in C3-epimer of 25(OH)D3 [epi-25(OH)D3] (7,8) 
have also been observed in some studies. Nonetheless, the underlying mechanisms of these 
pregnancy-induced changes in circulating vitamin D metabolites are largely unknown. 
The placenta is an organ of pregnancy that expresses all components of the vitamin D 
metabolic pathway (i.e., megalin-cubilin receptors (LRP2 and CUBN, respectively) (9,10), 25-
hydroxylase (CYP2R1) (11), 1α-hydroxylase (CYP27B1) (12,13), and 24-hydroxlyase (CYP24A1) 
(11,14)), and thus, could mediate the observed pregnancy-induced alterations in circulating 
concentrations of the vitamin D metabolites in the maternal compartment. Indeed, placental 
production of 1,25(OH)2D3 and 24,25(OH)2D3 by the actions of CYP27B1 and CYP24A1 on 
25(OH)D3 have been established (12,15,16). Moreover, although the extent to which the placenta 
contributes to a doubling of circulating 1,25(OH)2D3 as compared to the kidney is still debated, it 
is unequivocally confirmed in nephrectomized animals that placentally produced 1,25(OH)2D3 can 
enter maternal circulation (17,18). However, it remains unclear whether placental CYP2R1 
produces 25(OH)D3 from parent vitamin D3, and whether this metabolite can enter maternal blood. 
In addition, because the kidney internalizes DBP-bound 25(OH)D through the megalin-cubilin 
receptors from the glomerular filtrate (19), presence of this receptor complex in placental 
membrane along with a dramatic increase in DBP during pregnancy support the possibility that 
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the placenta takes up 25(OH)D bound to DBP in a tissue-specific manner and regulates the 
production of several forms of vitamin D metabolites. Lastly, the role of the placenta in mediating 
circulating vitamin D metabolites such as 24,25(OH)2D3 and epi-25(OH)D3 is under investigated.   
To advance current understanding of placental vitamin D metabolism and its impact on the 
maternal compartment, this study examined associations between biomarkers of vitamin D 
metabolism in placental tissue and maternal blood obtained from pregnant women participating in 
a long-term controlled feeding study. Associations between placental vitamin D metabolites and 
placental expression of vitamin D metabolizing genes were also examined. In addition, a human 
placental cell culture model was used to explore placental uptake of 13C-labeled vitamin D3 and its 
metabolic fate.  
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METHODS 
Human Feeding Study 
Study participants, study design, and sample collection 
Twenty-four third-trimester singleton pregnant women (26-29 weeks gestation; > 21yr) in 
good health status were recruited from Ithaca, New York during 2009-2010 to participate in a 12-
week feeding study that featured two choline intake levels and provided an average total intake of 
511 IU vitamin D/d [311 IU from a diet and 200 IU from a prenatal multivitamin supplement 
(Pregnancy Plus; Fairhaven Health LLC)], 1.6 g calcium/d, and 1.9 g phosphorus/d (8,20,21). 
Venous blood samples obtained at week 0 (study-baseline) and week 10 (representing study-end), 
along with placental tissue samples collected at delivery, were used for measurements of vitamin 
D metabolic and genomic parameters. The study protocol was approved by the Institutional 
Review Board for Human Study Participant Use at Cornell University and at Cayuga Medical 
Center where babies were delivered. All participants provided their informed consent prior to study 
entry. 
 
Measurements of vitamin D metabolites in blood and placental tissues 
Serum 25(OH)D3, serum epi-25(OH)D3, and plasma 24,25(OH)2D3 were quantified using 
a stable isotope dilution LC-MS/MS methodology as previously described (8). Plasma 
1,25(OH)2D3 (Immunodiagnostic Systems) and DBP (R&D Systems) were quantified using 
ELISA kits. Estimation of free 25(OH)D3 concentrations was performed using a previously 
published equation (22).   
Placental 25(OH)D3 and 24,25(OH)2D3 were extracted from homogenized placental tissues 
(0.4 g) in 1 mL of methanol following liquid-liquid extraction (addition of 600 μL acetonitrile,   
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1 mL MTBE, 25 μL internal standard), solid-phase extraction using Oasis HLB cartridges (3 cc/60 
mg), and 0.1 mg/mL DMEQ-TAD derivatization (23, 24). An internal standard solution containing  
215 μmol/L d3-25(OH)D3 (IsoSciences) and 1.7 μmol/L d6-24,25(OH)2D3 (Toronto Research 
Chemicals Inc.) was added to the homogenized tissues at the beginning of the extraction (24). 
Extracts were resuspended in 110 μL of 60:40 methanol/water solution and injected onto an LC-
MS/MS system to quantify the vitamin D metabolites. LC-MS/MS conditions followed the 
protocol for circulating 24,25(OH)2D3 (8).   
 
Quantitative real-time PCR of the vitamin D machinery in placental tissues 
RNA was extracted from placental tissue samples using RNeasy Mini kit (Qiagen), and the 
concentrations were determined using a NanoDrop ND-1000 instrument (Thermo). Reverse 
transcription was performed using the High Capacity cDNA Reverse Transcription kit (Thermo 
Fisher Scientific), and quantitative real-time PCR (RT-PCR) was conducted using an Applied 
Biosystems ABI 7300 system. The TaqMan Gene Expression Assays (Thermo Fisher Scientific) 
were Hs00167999_m1 (CYP24A1), Hs00168017_m1 (CYP27B1), Hs01379776_m1 (CYP2R1), 
Hs01119018_g1 (LRP2), and Hs00153607_m1 (CUBN). The reaction conditions were 50°C for 2 
min, 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min. Based on the 2-ΔΔCt 
method (25), data were expressed as fold change in mRNA expression of the genes of interest 
which were normalized to the housekeeping gene [beta-glucuronidase (GUSB; Hs99999908_m1)] 
and relative to the calibrator.  
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In Vitro Placental Trophoblast Cell Culture Model 
HTR-8/SVneo cell culture  
HTR-8/SVneo cells which are immortalized human first-trimester placental extravillous 
trophoblasts were obtained as a gift from Dr. Charles H. Graham (Queen’s University, Canada). 
The cells (passage number 17-21) were plated on a culture dish (BD Biosciences) at a seeding 
density of 1.39 x 106 cells/dish, and cultured in standard RPMI1640 medium which contained 
1.25-5% fetal bovine serum (FBS), 2 mM L-glutamine (all from Corning Life Sciences), and each 
vitamin D treatment [i.e., 13C2-vitamin D3, 
13C5-25(OH)D3,  unlabeled-vitamin D3, 25(OH)D3, or 
1,25(OH)2D3] at 37˚C in a humidified atmosphere of 5% CO2/95% air. 100% ethanol was added 
to the standard medium to serve as a control treatment (0.1% ethanol). Cell counts and viability 
were determined in duplicate using a TC10TM cell counter (Bio-Rad) and a trypan blue exclusion 
test, respectively. The experiment was repeated three times. Within each replication, each 
treatment was performed in triplicate. 
 
Unlabeled vitamin D treatment and quantitative RT-PCR of vitamin D metabolic enzymes 
To examine effects of vitamin D exposure [vitamin D3, 25(OH)D3, 1,25(OH)2D3] on gene 
expression response of vitamin D metabolic enzymes in the placenta, HTR-8/SVneo cells were 
cultured for 72-h with one of the unlabeled vitamin D or vitamin D metabolites. Final vitamin D 
concentrations of each treatment were 2,500 nM, 5,000 nM, and 10,000 nM of vitamin D3 (Cayman 
Chemical), 500 nM of 25(OH)D3 (Cayman Chemical), and 100 nM of 1,25(OH)2D3 (Sigma-
Aldrich).  
From harvested cell pellets, total RNA was extracted (PerfectPure RNA Cell and Tissue 
kit), quantified and subjected to reverse transcription and quantitative RT-PCR. The TaqMan Gene 
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Expression Assays for CYP24A1, CYP27B1, CYP2R1 and GUSB, reaction conditions, and data 
expression method were the same as those described above in the quantitative RT-PCR protocol 
used for the placental tissues.  
 
13C-labeled vitamin D treatment [13C2-vitamin D3, 13C5-25(OH)D3] and measurements of 
13C-labeled vitamin D metabolites from cells and media  
To explore the metabolic fate of vitamin D3, HTR-8/SVneo cells were cultured for 24-h, 
72-h, and 96-h with either 13C2-vitamin D3 (Cambridge Isotope Laboratories) or 
13C5-25(OH)D3 
(IsoSciences LLC), resulting in final concentrations of 5,000 nM or 500 nM, respectively. These 
dosing concentrations of 13C2-vitamin D3 and 
13C5-25(OH)D3 were selected using data from the 
unlabeled vitamin D treatment. At each culture time point, the cells and media from the treatments 
and control were harvested separately and stored at -80˚C until measurements.  
13C-labeled vitamin D metabolites (i.e., 13C-vitamin D3, 
13C-25(OH)D3, 
13C-1,25(OH)2D3, 
13C-24,25(OH)2D3) were extracted from the cells, which were sonicated in 200 μL deionized water, 
based on liquid-liquid and solid-phase extractions described for placental tissue vitamin D 
metabolites, but followed by 50 μL of 1 mg/mL PTAD derivatization (23,26). Media (15 mL) was 
mixed with 15 mL methanol and 25 μL internal standard, and subsequently underwent the solid-
phase extraction and the derivatization. An internal standard solution mix for 13C2-vitamin D3 
treatment and ethanol control contained d6-vitamin D3, d3-25(OH)D3, d3-1,25(OH)2D3, and d6-
24,25(OH)2D3, while an internal standard solution for 
13C5-25(OH)D3 treatment contained d3-
25(OH)D3, d3-1,25(OH)2D3, and d6-24,25(OH)2D3. 10 μL of extracts diluted with 0.1% formic 
acid in water (+5 mM methylamine) were injected and separated by an LC-MS/MS system 
(Ultimate 3000 UHPLC coupled to Thermo Scientific QE-MS) with Waters BEH C18 columns 
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(2.5 μm; 2.1 x 50mm) (26). Extracts from the ethanol control were injected twice with extracts 
from either 13C2-vitamin D3 or 
13C5-25(OH)D3 treatment for separate comparisons. Elution of the 
analytes of interest at a flow rate of 250 μL/min was optimized under the following conditions: 
40% of 0.1% formic acid in methanol and 60% of 0.1% formic acid in water (+5mM methylamine) 
at 0 min; linear gradient from 40% to 70% of 0.1% formic acid in methanol (0-5th min); 70% of 
0.1% formic acid in methanol (5-9th min); linear gradient from 70% to 40% of 0.1% formic acid 
in methanol (9-12th min); and 40% of 0.1% formic acid in methanol (12-17th min). The analytes of 
interest were detected in electrospray ionization (ESI)-positive ion mode. Details about 
quantification including transition pairs and calibration ranges for the analytes of interest in 13C-
labeled vitamin D treatments are provided in the Table 2.1 and Supplemental Table S2.1, 
respectively. 
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Table 2.1. Transition pairs for the analytes of interest in the 13C-labeled vitamin D treatments 
 
Analytes of interest 
Transition pairs 
13C2-vitamin D3 treatment 
13C5-25(OH)D3 treatment 
Vitamin D3 m/z 591.43 (280.1>298.1) - 
d6-vitamin D3 m/z 597.43 (280.1>298.1) - 
13C2-vitamin D3 m/z 593.43 (280.1>298.1) - 
25(OH)D3 m/z 607.42 (280.1>298.1) m/z 607.42 (280.1>298.1) 
d3-25(OH)D3 m/z 610.42 (283.1>301.1) m/z 610.42 (283.1>301.1) 
13C2-25(OH)D3 m/z 609.42 (281.1>299.1) - 
13C5-25(OH)D3 - m/z 612.42 (280.1>298.1) 
24,25(OH)2D3 m/z 623.42 (280.1>298.1) m/z 623.42 (280.1>298.1) 
d6-24,25(OH)2D3 m/z 629.42 (280.1>298.1) m/z 629.42 (280.1>298.1) 
13C2-24,25(OH)2D3 m/z 625.42 (280.1>298.1) - 
13C5-24,25(OH)2D3 - m/z 628.42 (280.1>298.1) 
1,25(OH)2D3 m/z 623.42 (296.1>314.1) m/z 623.42 (296.1>314.1) 
d3-1,25(OH)2D3 m/z 626.42 (299.1>317.1) m/z 626.42 (299.1>317.1) 
13C2-1,25(OH)2D3 m/z 625.42 (296.1>314.1) - 
13C5 1,25(OH)2D3 - m/z 628.42 (296,1>314.1) 
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Statistical analysis 
Differences between baseline and study-end circulating vitamin D metabolites among 
pregnant women were tested using a paired t-test except for epi-25(OH)D3 which was analyzed by 
the Wilcoxon signed-rank test. To examine associations of placental mRNA abundance of the 
vitamin D machinery with vitamin D metabolites in blood and placental tissues, a linear mixed 
model (LMM) was constructed. Each placental and circulating vitamin D metabolite were entered 
into the model as a fixed effect, while the participant identifier was entered as a random effect. 
Covariates considered in initial models are shown in Table 2.2 and Supplemental Table S2.2, 
and those with a significance level of P < 0.2 were retained in final models. In addition, 
associations between placental and circulating vitamin D metabolites were assessed using a 
Pearson’s correlation analysis.  
To examine changes in concentrations of intracellular and extracellular 13C-labeled vitamin 
D metabolites from HTR-8/SVneo cells with 13C-labeled vitamin D treatments, the LMM and the 
Bonferroni correction was used. Culture time (24-h, 72-h, or 96-h), location of the metabolite 
extraction (cell or medium), and their interaction were fixed effects, and experiment number (1st, 
2nd or 3rd experiments) and sample identifier nested within the experiment number were random 
effects. The LMM was also used to assess changes in product:precursor ratios in the vitamin D 
metabolic pathway. Differences in enzyme gene expression among the vitamin D treatment groups 
(unlabeled) in the cells were tested using a 1-factor ANOVA.   
All analyses were conducted using JMP Pro 12 (SAS Institute), STATA 14 (StataCorp LP), 
and SigmaPlot 11 (Systat Software). Data not normally distributed were ln-transformed and are 
presented as arithmetic means±SDs or geometric means (95% CIs), unless otherwise specified. P 
values were 2-tailed and considered significant at < 0.05. 
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Table 2.2. Characteristics and concentrations of circulating and placental vitamin D metabolites 
among the third-trimester pregnant women1,2 
 
Characteristics Pregnant women (n =24) 
Age, y 29 ± 3 
Prepregnancy BMI, median [IQR], kg/m2 23 [21, 26] 
Ethnicity, n  
    Caucasian / African American / Latino / Asian / Other 14 / 1 / 4 / 4 / 1 
Season at study entry, n   
    April–September / October–March 13 / 11 
Gestational age at birth, weeks 39.9 ± 0.7 
Circulating vitamin D metabolites  Baseline Study-end 
25(OH)D3, nmol/L 85.3 ± 28.6a 96.8 ± 33.0b 
1,25(OH)2D3, geometric means (95% CIs), pmol/L 290 (235, 357)
a 312 (258, 379)a 
24,25(OH)2D3, nmol/L 11.4 ± 6.1a 12.8 ± 5.2a 
Free 25(OH)D3, geometric means (95% CIs), pmol/L 15.7 (11.8, 20.9)
a 19.4 (15.0, 25.1)b 
Epi-25(OH)D3, nmol/L 3.2 ± 2.2a 4.5 ± 3.5b 
24,25(OH)2D3 : 25(OH)D3 0.13 ± 0.04a 0.13 ±  0.03a 
DBP, µg/mL 461 ± 247b 422 ± 233a 
Placental vitamin D metabolites Delivery 
25(OH)D3, pmol/g 20.9 ± 8.2 
24,25(OH)2D3, pmol/g 2.2 ± 1.5 
24,25(OH)2D3 : 25(OH)D3 0.10 ± 0.04 
 
1 Values are mean ± SD, unless otherwise indicated. For circulating vitamin D metabolites, values 
in a row with a superscript letter indicate significant differences between baseline and study-end 
(i.e., a < b). P < 0.05.   
2 DBP, vitamin D binding protein; Epi-25(OH)D3, C3 epimer of 25-hydroxyvitamin D3; Free 
25(OH)D3, free 25-hydroxyvitamin D3; 25(OH)D3, 25-hydroxyvitamin D3; 1,25(OH)2D3, 1,25-
dihydroxyvitamin D3; 24,25(OH)2D3, 24,25-dihydroxyvitamin D3 
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RESULTS 
Characteristics and measures of vitamin D metabolites in blood and placenta among 
pregnant women 
 Table 2.2 depicts the characteristics of the third-trimester pregnant women along with their 
vitamin D metabolite concentrations in blood at baseline and study-end, and in placental tissue. 
Differences were detected between baseline and study-end for 25(OH)D3, free 25(OH)D3, epi-
25(OH)D3, and DBP, whereas no differences were detected between these study time points for 
1,25(OH)2D3, 24,25(OH)2D3, and the 24,25(OH)2D3:25(OH)D3 ratio.  
 
Associations between placental and circulating vitamin D metabolites   
A strong positive correlation (r = 0.83, P < 0.001) was detected between placental 
25(OH)D3 and placental 24,25(OH)2D3 at delivery. Moreover, these placental vitamin D 
metabolites were significantly correlated with the majority of circulating vitamin D metabolites 
through time (Figure 2.1). Placental 25(OH)D3 showed strong positive correlations with 
circulating 25(OH)D3 (Figure 2.1A) and 24,25(OH)2D3 (Figure 2.1B) at both baseline and study-
end. Placental 25(OH)D3 was also positively correlated with baseline circulating 
24,25(OH)2D3:25(OH)D3 ratio (Figure 2.1C), study-end free 25(OH)D3 (Figure 2.1D), and study-
end epi-25(OH)D3 (Figure 2.1E). In addition, placental 24,25(OH)2D3 showed positive 
correlations with circulating 25(OH)D3 (Figure 2.1F) and 24,25(OH)2D3 (Figure 2.1G) throughout 
the study, and placental 24,25(OH)2D3 was positively correlated with study-end epi-25(OH)D3 
(Figure 2.1H).  
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Figure 2.1 Relationships between placental and circulating vitamin D metabolites in pregnant 
women (n = 24) by study time point: (A) placental 25(OH)D3 and serum 25(OH)D3; (B) placental 
25(OH)D3 and plasma 24,25(OH)2D3 (C) placental 25(OH)D3 and circulating 
24,25(OH)2D3:25(OH)D3 ratio; (D) placental 25(OH)D3 and circulating free 25(OH)D3; (E) 
placental 25(OH)D3 and serum epi-25(OH)D3; (F) placental 24,25(OH)2D3 and serum 25(OH)D3; 
(G) placental 24,25(OH)2D3 and plasma 24,25(OH)2D3; (H) placental 24,25(OH)2D3 and serum 
epi-25(OH)D3. Study-baseline values are presented in open squares with dashed line slopes and 
study-end values are presented in closed squares with solid line slopes. Free 25(OH)D3 was ln-
transformed.  
 
 
Associations of placental gene expression of the vitamin D machinery with placental vitamin 
D metabolites   
Placental LRP2 mRNA abundance was positively associated with placental 
24,25(OH)2D3:25(OH)D3 ratio [R
2 = 0.62; β = 1873.54 (235.39, 3511.68); P = 0.028] and placental 
25(OH)D3 [R
2 = 0.44; β = 6.51 (1.67, 11.34); P = 0.011]. Further, placental CYP2R1 and CYP24A1 
mRNA abundance tended to be inversely associated with placental 24,25(OH)2D3:25(OH) D3 ratio 
[For CYP2R1, R2 = 0.52, β = -9.06 (-18.47, 0.34), P = 0.058;  For CYP24A1, R2 = 0.20, β = -8.72 
(-17.43, -0.0042), P = 0.050]. 
   
Associations of placental gene expression of the vitamin D machinery with circulating 
vitamin D metabolites 
Placental CYP24A1 mRNA abundance was positively associated with circulating 
1,25(OH)2D3 at both baseline and study-end (Table 2.3), and with baseline circulating 25(OH)D3, 
24,25(OH)2D3, free 25(OH)D3 and epi-25(OH)D3. Placental LRP2 mRNA abundance was 
positively associated with circulating 25(OH)D3 and epi-25(OH)D3 at both baseline and study-end, 
and with study-end free 25(OH)D3 (Table 2.3). Placental CUBN mRNA abundance was positively 
associated with circulating 25(OH)D3 and 1,25(OH)2D3 at both study time points (Table 2.3), 
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while placental CYP2R1 mRNA abundance was positively associated with circulating 
1,25(OH)2D3 throughout the study, and with baseline epi-25(OH)D3 (Table 2.3). Finally, placental 
CYP27B1 mRNA abundance was positively associated with baseline epi-25(OH)D3 and study-end 
1,25(OH)2D3, and tended to be associated with baseline 25(OH)D3 (Table 2.3).   
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Table 2.3  
Associations of placental gene transcript abundance of the vitamin D metabolic machinery with 
circulating vitamin D metabolites among pregnant women (n = 24)1-3 
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Placental 
Genes 
Circulating   
Vitamin D Metabolites 
R2 β (95% CI) P Value 
LRP2 Baseline    
 25(OH)D3 0.51 3.3 (1.7, 5.0) < 0.001 
 
 
Epi-25(OH)D3 0.58 22 (-0.61, 44) 0.06 
 Study-end    
 25(OH)D3 0.64 2.5 (1.2, 3.9) 0.001 
 Free 25OHD3 0.82 8.9 (5.2, 13) 0.0003 
 Epi-25(OH)D3 0.55 16 (5.5, 26) 0.005 
CUBN Baseline    
 25(OH)D3 0.31 0.016 (0.0026, 0.029) 0.02 
 1,25(OH)2D3 0.47 0.0035 (0.0015, 0.0052) 0.001 
 Study-end    
 25(OH)D3 0.49 0.020 (0.0073, 0.032) 0.004 
 1,25(OH)2D3 0.53 0.0037 (0.0019, 0.0056) < 0.001 
CYP2R1 Baseline    
 1,25(OH)2D3 0.34 0.0025 (0.0009, 0.0042) 0.004 
 Epi-25(OH)D3  0.56 0.23 (0.11, 0.34) < 0.001 
 Study-end    
 1,25(OH)2D3 0.32 0.0021 (0.0007, 0.0034) 0.006 
CYP27B1 Baseline    
 25(OH)D3 0.54 0.0095 (-0.0007, 0.020) 0.06 
 Epi-25(OH)D3 0.40 0.19 (0.079, 0.31) 0.002 
 Study-end    
 1,25(OH)2D3 0.57 0.0022 (0.0007, 0.0037) 0.007 
CYP24A1 Baseline    
 25(OH)D3 0.43 0.024 (0.010, 0.037) 0.002 
 1,25(OH)2D3 0.40 0.0043 (0.0019, 0.0067) 0.001 
 24,25(OH)2D3 0.21 0.069 (0.0071, 0.13) 0.03 
 Free 25(OH)D3  0.33 0.075 (0.024, 0.13) 0.007 
 Epi-25(OH)D3  0.56 0.38 (0.22, 0.54) < 0.001 
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Table 2.3 (Continued) 
   
 Study-end    
CYP24A1 1,25(OH)2D3 0.45 0.0036 (0.0016, 0.0056) 0.001 
 
 
1 Data were derived from the covariate-adjusted linear mixed models.   
2 All placental vitamin D-related gene transcript abundance (dependent variables) were ln-
transformed except for LRP2.   
3 No association achieved statistical significance between placental gene expression and circulating 
vitamin D metabolites unless listed in this table.  
 
 
Effects of vitamin D exposure on placental gene expression of the vitamin D metabolic 
enzymes in HTR-8/SVneo cell cultures 
We examined effects of vitamin D treatment [unlabeled vitamin D3, 25(OH)D3, 
1,25(OH)2D3] on gene expression response of vitamin D metabolic enzymes in the placental cells. 
1,25(OH)2D3 (100 nM) and 25(OH)D3 (500 nM) treatments up-regulated (P < 0.05) CYP24A1 
gene expression by 734- and 566-fold, respectively, compared to the ethanol control at 72-h 
(Figure 2.2). Similarly, the higher concentrations of vitamin D3 treatments yielded a dose-response 
increase (P < 0.05) in CYP24A1 mRNA abundance (43-fold at 2,500 nM, 114-fold at 5,000 nM, 
and 142-fold at 10,000 nM compared to the control; Figure 2.2). In contrast, vitamin D3, 25(OH)D3, 
or 1,25(OH)2D3 treatment did not influence CYP27B1 and CYP2R1 mRNA expression 
(Supplemental Table S2.3).  
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Figure 2.2. Responses of CYP24A1 mRNA abundance in HTR-8/SVneo cells to vitamin D 
(unlabeled) treatment at 72-h. Values are means ± SE. Data were obtained from three separate 
experiments with each experiment containing three replicates per vitamin D treatment, and were 
analyzed after log10 transformation. Means without a common letter differ, P < 0.05. 
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Intracellular and extracellular concentrations of 13C-labeled vitamin D metabolites in HTR-
8/SVneo cell cultures 
 In the 13C5-25(OH)D3 treatment (Figure 2.3A-2.3C), intracellular 
13C5-25(OH)D3 
concentrations decreased by 53% (P < 0.001) (Figure 2.3A), and extracellular 13C5-25(OH)D3 
concentrations (i.e., treatment concentrations in the media) decreased by 90% (P < 0.001) from 
24-h to 96-h. In contrast, intracellular and extracellular concentrations of 13C5-1,25(OH)2D3 
increased by 86% (P < 0.001) and 18% (P = 0.017), respectively, from 24-h to 96-h (Figure 2.3B). 
Although intracellular 13C5-24,25(OH)2D3 concentrations increased slightly (15%; P = 0.008) from 
24-h to 96-h (Figure 2.3C), extracellular 13C5-24,25(OH)2D3 concentrations decreased (-70%;    
P < 0.001).   
In the 13C2-vitamin D3 treatment (Figure 2.3D-2.3G), intracellular 
13C2-vitamin D3 
concentrations decreased (-42%; P < 0.001) from 24-h to 96-h (Figure 2.3D), as did extracellular 
13C2-vitamin D3 concentrations (-86%; P < 0.001). In addition, intracellular 
13C2-25(OH)D3 
concentrations increased by 37% (P < 0.001) from 72-h to 96-h (Figure 2.3E), whereas 
extracellular 13C2-25(OH)D3 concentrations remained stable. Finally, extracellular 
13C2-
1,25(OH)2D3 and 
13C2-24,25(OH)2D3 concentrations increased by 203% (P < 0.001) and 75%   
(P < 0.001), respectively, from 72-h to 96-h (Figure 2.3F, 2.3G). None of 13C-labeled vitamin D 
metabolites were detected in the ethanol control.  
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Figure 2.3. Intracellular and extracellular concentrations of 13C-labeled vitamin D metabolites 
from HTR-8/SVneo cells incubated with 13C5-25(OH)D3 (A-C) or 
13C2-vitamin D3 (D-G) for 24-
h, 72-h, and 96-h: (A) 13C5-25(OH)D3, treatment; (B) 
13C5-1,25(OH)D3, product; (C) 
13C5-
24,25(OH)D3, product; (D) 
13C2-vitamin D3, treatment; (E) 
13C2-25(OH)D3, product; (F) 
13C2-
1,25(OH)D3, product; (G) 
13C2-24,25(OH)D3, product. All concentrations are predicted geometric 
means (95% CIs) derived from the covariate-adjusted linear mixed models. Values were obtained 
from three separate experiments with each experiment containing three replicates per vitamin D 
treatment at a time point. Different letters denote changes in concentrations through time within 
cells or media, P < 0.05. Asterisks (*) denote differences in concentrations between cells and 
media at a time, P < 0.05. None of 13C-labeled vitamin D metabolites were detected in the ethanol 
control treatment.   
 
Ratios of product to precursor in the 13C-labeled vitamin D metabolic pathway in HTR-
8/SVneo cell cultures 
 In the 13C5-25(OH)D3 treatment, ratios of intracellular 
13C5-1,25(OH)2D3:
13C5-25(OH)D3 
and  13C5-24,25(OH)2D3:
13C5-25(OH)D3 increased (P < 0.001) from 24-h to 96-h (Figure 2.4A). 
In the 13C2-vitamin D3 treatment, extracellular:intracellular ratios for 
13C2-1,25(OH)2D3:
13C2-
25(OH)D3 and 
13C2-24,25(OH)2D3: 
13C2-25(OH)D3 increased (P < 0.001) from 72-h to 96-h 
(Figure 2.4B). At each time point, the 24,25(OH)2D3:25(OH)D3 ratio was significantly higher   
(P < 0.001) than the 1,25(OH)2D3:25(OH)D3 ratio in both 
13C5-25(OH)D3 and 
13C2-vitamin D3 
treatments.   
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Figure 2.4. Production of 13C-1,25(OH)2D3 and 
13C-24,25(OH)2D3 that are normalized to the 
precursor, 13C-25(OH)D3, in HTR-8/SVneo cells incubated with 
13C5-25(OH)D3 (A) or 
13C2-
vitamin D3 (B) for 24-h, 72-h, and 96-h. All ratios are predicted geometric means (95% CIs) 
derived from the covariate-adjusted linear mixed models. Values were obtained from three 
separate experiments with each experiment containing three replicates per vitamin D treatment at 
a time point. Different letters denote changes within 1,25(OH)2D3:
13C-25(OH)D3 ratio or 
24,25(OH)2D3:25(OH)D3 ratio through time, P<0.05. Asterisks (*) denote differences between 
1,25(OH)2D3:25(OH)D3 ratio and 24,25(OH)2D3:25(OH)D3 ratio at a time, P < 0.05. None of 
13C-
labeled vitamin D metabolites were detected in the ethanol control treatment.   
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DISCUSSION 
To the best of our knowledge, this is the first study to comprehensively assess associations 
between placental vitamin D metabolites and placental gene expression of vitamin D metabolic 
components as well as their relationships with circulating vitamin D metabolites. Human placental 
trophoblast cells were also used to investigate vitamin D uptake, metabolism, and secretion in 
response to treatment with different vitamin D metabolites in vitro. Findings from the associations 
between placental and circulating vitamin D biomarkers of our human study suggest that: (i) the 
import of 25(OH)D3 by the placenta occurs mostly through a regulated process; (ii) the placenta 
partitions the precursor, 25(OH)D3, between synthetic or catabolic pathways thereby regulating 
the supply of 1,25(OH)2D3; and (iii) the placenta plays an active role in the uptake and metabolism 
of C3-epimeric forms of vitamin D3. Remarkably, we also demonstrate that placental trophoblast 
cells produce and secrete not only 1,25(OH)2D3 and 24,25(OH)2D3, but also, for the first time, 
25(OH)D3 from parent vitamin D3.  
 
Characterization of placental vitamin D metabolism and its putative role in modulating 
circulating concentrations of vitamin D metabolites 
Numerous positive associations between placental and circulating concentrations of 
vitamin D metabolites were found in the present study (Figure 2.1). Further, and more notably, 
positive associations (P < 0.03) were observed between placental tissue mRNA abundance of 
vitamin D metabolic components and circulating vitamin D metabolites (i.e., LRP2 with 25(OH)D3, 
free 25(OH)D3 and epi-25(OH)D3; CUBN with 25(OH)D3 and 1,25(OH)2D3; CYP2R1 with epi-
25(OH)D3 and 1,25(OH)2D3; CYP24A1 with 25(OH)D3, 24,25(OH)2D3, epi-25(OH)D3 and 
1,25(OH)2D3; CYP27B1 with epi-25(OH)D3 and 1,25(OH)2D3). Overall, these data are consistent 
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with a modulatory role of the placenta on maternal circulating concentrations of vitamin D 
metabolites. 
Interestingly, the cellular uptake of 25(OH)D3, the major form of circulating vitamin D, 
appears to be mediated through the megalin-cubilin receptor complex and is thus a regulated 
process. For example, placental 25(OH)D3 showed a stronger positive correlation with total 
circulating 25(OH)D3 (comprised of free and DBP-bound forms), as compared to circulating free 
25(OH)D3, at both baseline and study-end. In addition, placental mRNA abundance of the low 
density lipoprotein-related protein 2 (LRP2, also known as megalin), the main endocytic receptor 
for DBP, was positively associated with total circulating 25(OH)D3 throughout the third trimester. 
Similarly, placental CUBN mRNA abundance (cubilin), which interacts with megalin to import 
DBP-bound vitamin D, was positively associated with total circulating 25(OH)D3, but not with 
free 25(OH)D3. Taken together, these data suggest that placental cellular uptake of 25(OH)D3 
occurs mainly through the megalin-cubilin receptor complex as opposed to simple diffusion. 
The placenta also appears to regulate the pool of bioactive vitamin D, 1,25(OH)2D3, by 
shunting its precursor, 25(OH)D3, between pathways which produce the active form [1,25(OH)2D3] 
or the catabolic form [24,25(OH)2D3] of vitamin D. Specifically, placental CYP27B1 mRNA 
abundance (encodes 1α-hydroxylase) tended to be positively associated with circulating baseline 
25(OH)D3 (P = 0.06) and study-end 1,25(OH)2D3 (P = 0.007), supporting a substrate-dependent 
placental production of 1,25(OH)2D3 (13,27). Placental CYP24A1 mRNA abundance (encodes 24-
hydroxylase) was also positively associated with circulating baseline 25(OH)D3 and 
24,25(OH)2D3. In addition, placental 25(OH)D3 was strongly correlated with placental 
24,25(OH)2D3 and circulating 24,25(OH)2D3 throughout the third trimester. These data 
collectively suggest that the placenta plays an active role in regulating the supply of 1,25(OH)2D3 
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by partitioning 25(OH)D3 between synthetic or catabolic pathways.   
A possible role in the uptake and metabolism of C3-epimeric forms of vitamin D3 by the 
placenta is also shown. The mRNA abundance of placental LRP2 was positively associated with 
circulating epi-25(OH)D3 at both baseline and study-end, suggesting that placental uptake of epi-
25(OH)D3, which can bind to DBP (28), is through the megalin-cubilin receptor system. In 
addition, the mRNA abundance of placental CYP2R1 (encodes 25-hydroxylase), CYP27B1 
(encodes 1α-hydroxylase), and CYP24A1 (encodes 24-hydroxylase) were positively associated 
with circulating epi-25(OH)D3 at baseline. Given that CYP27B1 and CYP24A1 show 
hydroxylating abilities of C3-epimers in vitro (29), these data suggest that the placenta could be a 
source of several C3-epimers [i.e., 3-epi-25(OH)D3, 3-epi-1,25(OH)2D3, and 3-epi-24,25(OH)2D3] 
during gestation. The finding that pregnant women have higher concentrations of circulating epi-
25(OH)D3 as compared to nonpregnant subjects (7,8) provide further support for this working 
hypothesis. Nonetheless, additional work is needed to establish the physiological role of C3-
epimers in pregnancy. 
 
Placental trophoblasts produce and secrete 25(OH)D3 along with 1,25(OH)2D3 and 
24,25(OH)2D3 
The cell culture component of this study shows that human placental trophoblast cells in 
vitro are capable of cellular uptake of parent vitamin D3, and more importantly, its use in the 
synthesis and export of 25(OH)D3. Specifically, 
13C2-25(OH)D3 increased in the cell pellets and 
media from HTR-8/SVneo cells incubated with 13C2-vitamin D3. Although others have also 
reported production of 25(OH)D3 by placental mitochondria incubated with vitamin D3 (30), our 
finding of 25(OH)D3 export by trophoblast cells provides compelling evidence that the placenta 
 66 
could be an extra-hepatic source of circulating 25(OH)D3. This notion is further supported by 
reports of higher serum 25(OH)D concentrations among pregnant women compared to 
nonpregnant control women consuming equivalent intakes of vitamin D (8). In addition, we show 
upregulation of CYP24A1 (24-hydroxlyase) in HTR-8/SVneo cells exposed to parent vitamin D3. 
Given that an inductive effect of 1,25(OH)2D3 on CYP24A1 transcription has also been shown in 
human syncytiotrophoblasts (31), data from the present study suggest that both parent vitamin D3 
and 1,25(OH)2D3 have regulatory roles in placental vitamin D metabolism.  
The cell culture component of this study also demonstrates biosynthesis and export of both 
1,25(OH)2D3 and 24,25(OH)2D3 from parent vitamin D3. Specifically, HTR-8/SVneo cells 
incubated with 13C2-vitamin D3 had increased extracellular concentrations of 
13C-1,25(OH)2D3 and 
13C-24,25(OH)2D3. Similar to prior reports (12,15,16,32), we also observed in vitro uptake of 
25(OH)D3, and its use for the synthesis and export of 1,25(OH)2D3 and 24,25(OH)2D3 in 
trophoblasts.  
 Notably, trophoblast cells generate and release greater amounts of 24,25(OH)2D3 than 
1,25(OH)2D3 from vitamin D3. When normalized to the precursor 
13C-25(OH)D3, cells produced 
significantly more 13C-24,25(OH)2D3 than 
13C-1,25(OH)2D3 at all time points in both 
13C2-vitamin 
D3 and 
13C5-25(OH)D3 treatments. One might expect that placental production of 1,25(OH)2D3 
would outweigh that of 24,25(OH)2D3 due to the weaker expression levels of placental CYP24A1 
than CYP27B1 (11,14) as well as methylation of the placental CYP24A1 gene promoter region (33) 
which could lead to its downregulation. However, we observed a robust induction of CYP24A1 
transcript abundance after treatments with both parent vitamin D3 and 25(OH)D3 which likely 
contributed to the greater production of 24,25(OH)2D3 in HTR-8/SVneo cells. In addition, others 
have shown that CYP24A1 (versus CYP27B1) has a higher affinity for 25(OH)D3 (34,35) which 
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would be expected to generate more 24,25(OH)2D3 relative to 1,25(OH)2D3.  
 
Study limitations 
Because protein expression levels of placental vitamin D machinery were not quantified in 
this study, we cannot exclude the possibility that associations of maternal circulating/placental 
vitamin D metabolites with the protein abundance of the metabolic genes might differ from those 
with the mRNA abundance. In addition, the HTR-8/SVneo cell culture may not be the best model 
that could fully represent human placental vitamin D metabolism. However, HTR-8/SVneo cells 
in the present study showed an extensive range of vitamin D metabolism from vitamin D3 uptake 
to 25(OH)D3, 1,25(OH)2D3 and 24,25(OH)2D3 production, thereby elucidating the metabolic fate 
of vitamin D3 within the cell as well as its secretory forms.  
 
Conclusions 
In this study, the placenta is identified as an extra-hepatic, extra-renal source of all forms of vitamin 
D metabolites [i.e., 25(OH)D3, 1,25(OH)2D3, and 24,25(OH)2D3]. As such, these placentally 
produced metabolites could influence maternal circulating vitamin D pools in a manner that is 
independent of dietary intake and other confounders. Further, like the kidney, the placenta appears 
to regulate cellular uptake of 25(OH)D3, the major form of circulating vitamin D, through its 
megalin-cubilin receptor complex. Finally, our data suggest that the placenta may metabolize and 
be a source of circulating C3-epimers of vitamin D. Taken together, these data provide compelling 
evidence that the placenta plays an active role in modulating the vitamin D metabolite profile in 
maternal circulation.           
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Supplemental Table S2.1. Calibration ranges for each 13C-labeled vitamin D metabolite in the 
13C2-vitamin D3 and
 13C5-25(OH)D3 treatments
1 
 13C2-vitamin D3 treatment 
13C5-25(OH)D3 treatment 
 pmol in  
media/sample2  
pmol in cell 
pellets/sample2 
pmol in 
media/sample 
Pmol in cell 
pellets/sample 
13C2-vitamin D3 250-25,000 250-25,000 - - 
13C2-25(OH)D3 1.25-1,250 2.5-500 - - 
13C5-25(OH)D3 - - 100-8,000 2.5-500 
13C2-24,25(OH)2D3 0.5-50 0.5-50 - - 
13C5-24,25(OH)2D3 - - 0.5-50 0.5-50 
13C2-1,25(OH)2D3 0.3-30 0.3-30 - - 
13C5-1,25(OH)2D3 - - 0.3-30 0.3-30 
 
1 Unlabeled 25(OH)D3, 1,25(OH)2D3, and 24,25(OH)2D3 were used to quantify 
13C2-25(OH)D3, 
13C2-24,25(OH)2D3, 
13C5-24,25(OH)2D3, 
13C2-1,25(OH)2D3, and 
13C5-1,25(OH)2D3 because these 
13C-labeled vitamin D metabolites were not commercially available.  
2 Each treatment at each culture time was performed in triplicate (i.e., sample 1,2,3), thus 13C-
labeled metabolites were extracted and quantified in media and cell pellets of each sample.  
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Supplemental Table S2.2. Gestational and neonatal outcomes and additional biochemical 
measurements of the third-trimester pregnant women1,2  
 
Gestational and neonatal characteristics               Pregnant women (n = 24) 
Parity (Primiparas / Multiparas), n 11 / 13 
Gestational weight gain, kg 15.9 ± 4.6 
Mode of delivery (Vaginal / Caesarean Section), n 17 / 5 
Multivitamin supplement use before entering the study (yes), n 20 
Choline intake during the study (480mg / 930mg), n 12 / 12 
GC rs7041 G>T polymorphism (GG / GT / TT) 3, n 8 / 10 / 6 
CYP2R1 rs10741657 A>G polymorphism (AA / AG / GG) 3, n 4 / 18 / 2 
CYP2R1 rs12794714 A>G polymorphism (AA / AG / GG) 3, n 5 / 18 / 1 
Infant gender (Boy / Girl), n 17 / 7 
Infant birth weight, kg 3.4 ± 0.3 
Infant head circumference, cm 34.2 ± 1.1 
Infant length, cm 50.3 ± 1.8 
Biochemical measures4 Baseline Study-end 
Calcium, mg/dL 8.7 ± 0.4a 8.9 ± 0.3b 
Phosphorus, mg/dL 3.4 ± 0.5a 3.5 ± 0.5a 
iPTH, geometric means (95% CIs), pg/mL   15.9 (12.2, 20.9)a 21.7 (17.8, 26.5)b 
 
1 Values are mean ± SD, unless otherwise indicated. For biochemical measures, values in a row 
with a superscript letter indicate significant differences between baseline and study-end (i.e., a < 
b). P < 0.05.   
2 CYP2R1, 25-hydroxylase gene; GC, vitamin D binding protein gene; iPTH, intact parathyroid 
hormone. 
3 Genotypes of single nucleotide polymorphisms in the vitamin D-related genes were determined 
by the Endpoint Genotyping on a Roche LightCycler 480 using the Applied Biosystems TaqMan 
Genotyping Assays (Life Technologies), as previously described (8). 
4 Serum calcium and phosphorus were quantified using an automated chemistry analyzer 
(Dimension Xpand Plus), and plasma iPTH was quantified using a Siemens Immulite 2000 
automated immunoassay, as previously described (8). 
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Supplemental Table S2.3. Responses of CYP27B1 and CYP2R1 mRNA abundance in HTR-
8/SVneo cells to vitamin D (unlabeled) treatment at 72-h1  
 
Treatment CYP27B1 CYP2R1 
Control 1.0 ± 0.1 1.0 ± 0.0 
Vitamin D3 5,000 nM 1.3 ± 0.2 1.1 ± 0.1 
25(OH)D3 500 nM 1.0 ± 0.1 1.2 ± 0.0 
1,25(OH)2D3 100 nM 1.0 ± 0.1 1.1 ± 0.0 
 
1 There was no effect of vitamin D3, 25(OH)D3, or 1,25(OH)2D3 on responses of CYP27B1 and 
CYP2R1 mRNA expression. 
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CHAPTER 3 
Maternal vitamin D biomarkers are associated with maternal and fetal bone turnover 
among pregnant women consuming controlled amounts 
of vitamin D, calcium, and phosphorus1,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Park H, Brannon PM, West AA, Yan J, Jiang X, Perry CA, Malysheva OV, Mehta S, Caudill MA. 
Maternal vitamin D biomarkers are associated with maternal and fetal bone turnover among 
pregnant women consuming controlled amounts of vitamin D, calcium, and phosphorus. Bone.  
2016 Dec; 95:183–191.  doi: 10.1016/j.bone.2016.12.002. Regarding the copyright of this article, 
authors have the right to include the article in their thesis or dissertation. 
2Supported by USDA National Institute of Food and Agriculture, Agriculture and Food Research 
Initiative Education and Literacy Initiative Predoctoral Fellowship 2016-67011-25174; NIH grant 
1R03HD080824-01A1; the Gerber Foundation grant 1843-3882; the American Egg Board/Egg 
Nutrition Center; and the Beef Checkoff, through the National Cattlemen’s Beef Association and 
Nebraska Beef Council. The funding sources had no role in the study design, interpretation of the 
data, and/or publication of results. 
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ABSTRACT 
Vitamin D plays a central role in calcium homeostasis; however, its relationship with bone 
turnover during pregnancy remains unclear due to a lack of studies that have rigorously controlled 
for vitamin D and other nutrients known to influence bone metabolism. Similarly, prior 
investigations of the effect of pregnancy on bone turnover relative to the nonpregnant state may 
have been confounded by varying intakes of these nutrients. Nested within a controlled intake 
study, the present investigation sought to quantify associations between maternal vitamin D 
biomarkers and biochemical markers of bone turnover among pregnant (versus nonpregnant) 
women and their fetuses under conditions of equivalent and adequate intakes of vitamin D and 
related nutrients. Changes in markers of bone turnover across the third trimester were also 
examined. Healthy pregnant (26–29 wk gestation; n = 26) and nonpregnant (n = 21) women 
consumed 511 IU vitamin D/d, 1.6 g calcium/d, and 1.9 g phosphorus/d for 10 weeks while 
participating in a controlled feeding study featuring two choline doses. Based on linear mixed 
models adjusted for influential covariates (e.g., BMI, ethnicity, and season), pregnant women had 
50–150% higher (P < 0.001) concentrations of bone resorption markers than nonpregnant women. 
Among pregnant women, increases in maternal 25(OH)D across the study period were associated 
(P < 0.020) with lower osteocalcin and deoxypyridinoline at study-end and higher fetal osteocalcin. 
In addition, maternal free 25(OH)D, 1,25(OH)2D and 24,25(OH)2D tended to be negatively 
associated (P ≤ 0.063) with maternal NTx at study-end, and maternal free 25(OH)D and 
24,25(OH)2D were positively associated (P ≤ 0.021) with fetal CTx. Similarly, maternal 3-epi-
25(OH)D3 was negatively related (P ≤ 0.037) to maternal NTx and deoxypyridinoline at study-
end. These declines in bone resorption markers resulting from higher vitamin D biomarker 
concentrations among pregnant women coincided with increases in their albumin-corrected serum 
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calcium concentrations, indicating that calcium transfer to the fetus was uncompromised. Notably, 
none of these associations achieved statistical significance among nonpregnant women. Overall, 
our study findings suggest that achieving higher maternal concentrations of vitamin D biomarkers 
might attenuate third-trimester bone resorption while ensuring sufficient calcium delivery to the 
fetus. 
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INTRODUCTION  
Pregnancy is characterized by a high maternal demand for calcium secondary to the laying 
down of bone in the fetus. This demand for calcium is mostly met by enhanced intestinal 
absorption of calcium which has been shown to double during pregnancy (1). Increased calcium 
mobilization from the bone is another mechanism to ensure adequate calcium to the developing 
fetus. However, maternal bone loss may ensue, particularly when the dominant adaptation of 
enhanced maternal intestinal calcium absorption does not fully meet calcium demands (2). 
Calcium homeostasis is regulated by vitamin D which influences intestinal calcium 
absorption, bone resorption and renal calcium absorption in a normal nonpregnant state. In 
pregnancy, a 2–3 times increase in 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations 
contributes, in part, to the doubling of intestinal calcium absorption (2). However, whether vitamin 
D plays a critical role in calcium mobilization from the bone during gestation is unclear. Animal 
studies have reported normal calcium homeostasis in fetuses from mothers that were either 
severely depleted in vitamin D (3,4), or deficient in the vitamin D receptor (VDR) (5,6), suggesting 
that fetal bone mineralization is independent of maternal vitamin D (7).  In humans, data are 
mixed with some, but not all (8–10), studies reporting an impact of maternal vitamin D status (25-
hydroxyvitamin D [25(OH)D]) on fetal bone development (11–15) and maternal bone turnover 
(16,17). These differences across studies may be secondary to diverse maternal intakes of calcium 
and phosphorus from food and supplements, which like vitamin D, play essential roles in bone 
biology and thus are important confounders (18–20). 
In addition to 25(OH)D, other forms of vitamin D may have critical roles in bone health. 
24,25-dihydroxyvitamin D [24,25(OH)2D] has been associated with bone mineralization in chicks 
and mice recovering from skeletal fracture (21,22). Free 25(OH)D was also shown to be associated 
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with bone mineral density in nonpregnant populations (23,24). Similarly, the C-3α epimer of 
25(OH)D3 [3-epi-25(OH)D3] was reported to have calcemic effects in cell culture studies (25,26). 
Nonetheless, very few studies have examined the relationship between these other biomarkers of 
vitamin D and markers of bone turnover during human pregnancy. 
As part of a controlled feeding study, our research group recently demonstrated that 
vitamin D metabolism varies among women in different reproductive states consuming adequate 
and equivalent amounts of vitamin D, calcium, and phosphorus. Specifically, higher circulating 
concentrations of several vitamin D biomarkers including 25(OH)D, 1,25(OH)2D, vitamin D 
binding protein (DBP), and 3-epi-25(OH)D3 were observed among pregnant women as compared 
to nonpregnant control women (27). As an extension of this feeding study, the present study sought 
to examine the relationships between maternal vitamin D biomarkers [i.e., 25(OH)D, 1,25(OH)2D, 
24,25(OH)2D, free 25(OH)D, 3-epi-25(OH)D3] and biochemical markers of bone turnover among 
pregnant women, nonpregnant women, and the newborns of the pregnant women. In addition, 
changes in bone turnover markers across the third trimester were examined in pregnant women 
who consumed adequate and equivalent intakes of vitamin D, calcium, and phosphorus. 
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MATERIALS AND METHODS 
Participants  
The study participants were twenty-six singleton pregnant women who entered the study 
at 26–29 weeks gestation and twenty-one nonpregnant control women of childbearing age. The 
women were recruited from Ithaca, New York (latitude 42.4°N) during 2009–2010 (28,29) and 
were 21–40 years old, non-smokers, and in good general health based on responses to a health-
history questionnaire, a blood chemistry profile, and a complete blood count. Pregnant women 
reported no use of alcohol throughout their prenatal period, and all women abstained from alcohol 
during the feeding study. The study protocol was reviewed and approved by the Institutional 
Review Board for Human Study Participant Use at Cornell University and the Cayuga Medical 
Center (the hospital where pregnant women delivered their infants). Written informed consent was 
obtained from all participants prior to study entry.  
 
Study design 
The current study was nested within a controlled feeding study in which the study 
participants consumed a 7-day rotational menu, and either 100 or 550 mg/d of supplemental 
choline (28). In addition, both pregnant and nonpregnant women consumed a prenatal 
multivitamin supplement on a daily basis containing vitamin D and calcium (Pregnancy Plus 
[Fairhaven Health LLC]), a DHA supplement (200 mg/d; Neuromins [Nature's Way Products]), 
and a potassium and magnesium supplement (3 times/wk.; General Nutrition Corp). During the 
week, pregnant and nonpregnant women consumed one meal each day along with their daily 
supplements at the onsite location under supervision. For offsite and weekend meals, food, 
beverages, and supplements were provided as carry-outs. 
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All pregnant and nonpregnant participants consumed an average daily intake of 511 ± 48 
IU vitamin D (311 ± 48 IU from food, 200 IU from a supplement), 1,622 ± 414 mg calcium 
(1,582 ± 414 mg from food and 40 mg from a supplement), and 1,877 ± 280 mg phosphorus 
for 10 weeks. Food estimates were based on the USDA National Nutrient Database for Standard 
Reference Release 28. 
 
Sample collection and processing  
 Fasting (10-h) EDTA venous blood and serum, as well as 24-h urine samples, were 
collected from all participants at study baseline (study week 0; corresponding to “the beginning of 
the third trimester”) and at study-end (study week 10; corresponding to “near term” before 
delivery). Fetal cord blood samples (n = 23) were also obtained at delivery in EDTA-coated tubes. 
Three cord blood samples were not retrieved: one participant delivered without notifying the 
research team, and two participants gave birth at home. The samples were processed and stored at 
−80 °C until analysis (28). 
 
Analytical measurements 
Vitamin D biomarkers and calcitropic hormones in pregnant and nonpregnant women 
Vitamin D biomarkers and calcitropic hormones were quantified in blood samples from 
pregnant and nonpregnant women. Serum 25(OH)D (i.e., the sum of 25(OH)D2 and 25(OH)D3), 
serum 3-epi-25(OH)D3, and plasma 24,25(OH)2D were quantified using isotope dilution liquid 
chromatography-mass spectrometry methodology (30,31) with modifications based on our 
instrumentation as previously described (27). Assay precision and accuracy were assessed by using 
the National Institute of Standards and Technology SRM and participating in the Vitamin D 
External Quality Assessment Scheme. Measurements of plasma 1,25(OH)2D (Immunodiagnostic 
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Systems, Inc., Scottsdale, AZ) and DBP (R&D Systems, Minneapolis, MN) were conducted using 
ELISA kits, and free 25(OH)D was estimated by an equation (32). Plasma intact parathyroid 
hormone (iPTH) was quantified by a Siemens Immulite 2000 automated immunoassay.   
 
Biochemical markers of bone turnover in pregnant and nonpregnant women 
Bone resorption markers  
ELISA kits were used to measure carboxy-terminal cross-linking telopeptide of type 1 
collagen (CTx; Immunodiagnostic Systems, Inc., Scottsdale, AZ), and amino-terminal cross-
linking telopeptide of type 1 collagen (NTx; MyBiosource, San Diego, CA) in plasma samples 
from pregnant and nonpregnant women. Deoxypyridinoline (DPD) was measured in urinary 
samples from pregnant and nonpregnant women using ELISA kits (Quidel Corporation, Athens, 
OH) and was subsequently expressed on the basis of creatinine concentrations. 
 
Bone formation markers 
Osteocalcin (OC) was quantified in plasma samples from pregnant and nonpregnant 
women using ELISA kits (R&D Systems, Minneapolis, MN), while alkaline phosphatase (ALP) 
was measured in serum samples from pregnant and nonpregnant women using an automated 
chemistry analyzer (Dimension Xpand Plus; Siemens Healthcare Diagnostics). 
 
Serum calcium and phosphorus  
An automated chemistry analyzer was used to measure serum total calcium, albumin, and 
phosphorus. Then, serum calcium concentrations were corrected for albumin concentrations.   
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Biochemical markers of bone turnover in neonates (cord blood) 
CTx and OC were measured in cord plasma obtained at delivery using ELISA kits 
mentioned above.  
 
Genotyping in pregnant and nonpregnant women  
Genotypes of three SNPs in the vitamin D binding protein gene (i.e., GC rs7041) and 1-
alpha-hydroxylase gene (i.e, CYP2R1 rs12794714 and CYP2R1 rs10741657) that are known to be 
associated with 25(OH)D concentrations (33) were determined among pregnant and nonpregnant 
women as previously described (27). 
 
Statistical analysis 
Data were analyzed by JMP Pro 11 (SAS Institute, Inc., Cary, NC). Differences in 
demographic characteristics and concentrations of vitamin D biomarkers between pregnant and 
nonpregnant women were assessed using independent t-tests (normally distributed continuous 
variables); Wilcoxon Rank Sum tests (non-normally distributed continuous variables); and Chi-
squared or Fisher’s exact tests (categorical variables). Changes in vitamin D biomarkers 
throughout the study within each group were tested using paired t-tests except for the change in 3-
epi-25(OH)D3 by Wilcoxon Signed-Rank test due to non-normal distribution. Because of different 
statistical approaches to assess vitamin D biomarkers, values reported in Table 3.1 are slightly 
different from the values in our previous report (27).  
Linear mixed models (LMMs) were used to examine differences/changes in bone turnover 
markers between the two groups at baseline and study-end. Reproductive state and time (i.e., 
baseline and study-end) were included as fixed factors, while participant identifier was entered as 
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a random factor. Initial models included several covariates such as age, ethnicity/race, BMI (pre-
pregnancy or baseline), education, prestudy multivitamin supplement use, season at study entry, 
genetic variants in vitamin D metabolism, and choline intake (480 or 930 mg/d). Covariates 
achieving statistical significance (P < 0.05) were retained in the final models. Bonferroni 
corrections were performed for post hoc comparisons between pregnant and nonpregnant groups 
at each study time point, and between baseline and study-end within each group. 
The relationships of maternal vitamin D biomarkers with maternal and fetal bone turnover 
markers were also assessed using LMMs. Candidate covariates for initial models included the 
variables mentioned above along with variables related to gestation and neonatal anthropometric 
outcomes [i.e., gestational age at birth, gestational weight gain, mode of delivery, parity, season at 
birth, neonate's gender, birthweight, head circumference, and length (Supplemental Table S3.1). 
Final models retained the covariates that achieved statistical significance (P < 0.05). LMMs were 
also used to assess differences in each bone marker between pregnant women and their fetuses. 
In all analyses, data that did not satisfy the normality and homogeneity of variance criteria 
were log (ln)-transformed, and influencing data that had studentized residuals > 3 were excluded 
(i.e., two ALP values). When covariates were retained in final models, data are presented as 
predicted means. P values < 0.05 for two-tailed tests were considered statistically significant. 
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Table 3.1  
Participant characteristics and concentrations of blood vitamin D biomarkers1,2 
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Pregnant (n = 26) Nonpregnant (n = 21) P-value 
Age, y 28 ± 3 29 ± 5 0.791 
Pre-pregnancy or baseline BMI, kg/m2 23.7 ± 3.1 23.5 ± 2.8 0.813 
Ethnicity, n    0.716 
    White  16  14   
    Non-White 10 7  
Multivitamin supplement uses before study entry, n  < 0.001 
    Yes  22  7  
    No 4 14  
CYP2R1 rs10741657 A>G polymorphism, n    0.012 
    AA    2 2   
    AG 20 8  
    GG 4 11  
CYP2R1 rs12794714 A>G polymorphism, n    0.153 
    AA  5 6  
    AG   20 11  
    GG 1 4  
GC rs7041 G>T polymorphism, n    0.873 
    GG  9 6  
    GT 11 9  
    TT 6 6  
Season at study entry, n      0.920 
    April–September  14 11  
    October–March 12 10  
Serum 25(OH)D, nmol/L    
    Baseline 88.7 ± 28.5 63.9 ± 24.7 0.004 
    Study-end 97.8 ± 32.1* 78.3 ± 25.3** 0.028 
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Table 3.1 (Continued)    
Plasma 1,25(OH)2D, geometric means (95% CIs), pmol/L   
    Baseline 283 (232, 344) 151 (129, 178) < 0.001 
    Study-end 303 (252, 364) 163 (139, 191) < 0.001 
Plasma 24,25(OH)2D, geometric means (95% CIs), nmol/L    
    Baseline 9.6 (7.5, 12.4) 9.1 (6.7, 12.5) 0.784 
    Study-end 11.4 (9.5, 13.8) 11.7 (9.2, 15.0)** 0.867 
Plasma DBP, geometric means (95% CIs), μg/mL    
    Baseline 405 (319, 515) 204 (164, 254) < 0.001 
    Study-end 370 (291, 470)** 205 (166, 255) < 0.001 
Serum 3-epi-25(OH)D3, nmol/L    
    Baseline 3.2 ± 2.1 1.9 ± 1.2 0.018 
    Study-end 4.5 ± 3.6* 2.5 ± 2.2 0.035 
Free 25(OH)D, geometric means (95% CIs), pmol/L    
    Baseline 16.0 (12.3, 20.8) 19.5 (14.9, 25.5) 0.291 
    Study-end 19.2 (15.1, 24.4)* 25.7 (20.8, 31.7)* 0.074 
 
1 Data are presented as means ± SDs, unless otherwise indicated. The P value in each row 
indicates a significant difference between pregnant and nonpregnant women. An asterisk beside a 
vitamin D biomarker indicates a significant difference between baseline and study-end within 
either pregnant or nonpregnant women: *, P < 0.05. **, P < 0.01. 
2 CYP2R1, 25-hydroxylase gene; DBP, vitamin D binding protein; 3-epi-25(OH)D3, C3 epimer of 
25-hydroxyvitamin D3; GC, vitamin D binding protein gene; 25(OH)D, 25-hydroxyvitamin D; 
1,25(OH)2D, 1,25-dihydroxyvitamin D; 24,25(OH)2D, 24,25-dihydroxyvitamin D.  
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RESULTS 
Participant characteristics and concentrations of blood vitamin D biomarkers  
  Demographic variables and vitamin D measures of the study participants (26 pregnant and 
21 nonpregnant women) are presented in Table 3.1. Briefly, no differences between pregnant and 
nonpregnant groups were detected in age, pre-pregnancy/baseline BMI, ethnicity, or season at 
study entry, whereas a greater portion of pregnant women had taken multivitamin supplements as 
compared to nonpregnant women prior to study entry. Pregnant women had higher 25(OH)D, 
1,25(OH)2D, DBP, and 3-epi-25(OH)D3 concentrations than nonpregnant women at baseline and 
study-end. Conversely, 24,25(OH)2D and free 25(OH)D concentrations did not differ between 
pregnant and nonpregnant women at either study time point. Over the course of the study (i.e., 
baseline to study-end), 25(OH)D, 3-epi-25(OH)D3, and free 25(OH)D increased, and 
24,25(OH)2D tended to increase (P = 0.057) among pregnant women. Increases in 25(OH)D, 
24,25(OH)2D and free 25(OH)D were observed among nonpregnant women.   
 
Associations of maternal vitamin D biomarkers with bone turnover markers in pregnant 
women and their fetuses 
Serum 25(OH)D was not associated with bone turnover markers at either baseline or study-
end. However, increases in serum 25(OH)D across the study period (i.e., concentration at study-
end – concentration at baseline) were associated negatively with maternal OC and DPD/Cr at 
study-end, and positively with fetal OC at delivery (Table 3.2). For 1,25(OH)2D, positive 
associations were observed at baseline and study-end with maternal OC and DPD/Cr, whereas 
negative associations were observed at these study time points with maternal NTx (Table 3.2). No 
associations with 24,25(OH)2D and maternal or fetal bone markers were detected at baseline. 
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However, study-end 24,25(OH)2D was positively related to fetal CTx at delivery, and tended to be 
negatively related to study-end maternal NTx (Table 3.2). Baseline free 25(OH)D was associated 
negatively with baseline maternal iPTH and ALP, and positively with fetal CTx (Table 3.2). In 
addition, study-end free 25(OH)D was negatively related to study-end maternal ALP and NTx 
(Table 3.2). Finally, baseline 3-epi-25(OH)D3 was negatively associated with study-end maternal 
ALP, while study-end 3-epi-25(OH)D3 was negatively related to study-end maternal DPD/Cr and 
ALP (Table 3.2). Moreover, the increase in 3-epi-25(OH)D3 through time was negatively 
associated with study-end maternal NTx (Table 3.2).  
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Table 3.2  
Associations of maternal vitamin D biomarkers with biochemical markers of bone turnover in 
mothers (n = 26) and their fetuses (n = 23)1-3 
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Maternal vitamin D 
markers 
 R2 β (95% CI) P  
Significant 
Covariates4,5 
Maternal bone markers at baseline 
 
1,25(OH)2D at baseline NTx 0.30 −0.002 (−0.0043, −5.0e-6) 0.050 BMI 
1,25(OH)2D at baseline DPD/Cr 0.38 0.001 (0.0004, 0.002) 0.010 rs10741657 
1,25(OH)2D at baseline OC 0.34 0.003 (0.0003, 0.006) 0.035 Season, 
rs10741657 
Free 25(OH)D at baseline iPTH 0.54 −0.020 (−0.040, −0.001) 0.040 Education, 
rs10741657  
Free 25(OH)D at baseline ALP 0.31 −0.012 (−0.023, −0.0005) 0.042 rs7041 
 Maternal bone markers at study-end  
Δ 25(OH)D6  DPD/Cr 0.49 −0.009 (−0.016, −0.002) 0.020 Age, rs10741657 
Δ 25(OH)D6 OC 0.74 −0.031 (−0.046, −0.017) < 0.001 BMI, gestational 
weight gain, 
rs10741657, 
rs12794714 
1,25(OH)2D at baseline DPD/Cr 0.60 0.001 (0.0001, 0.002) 0.033 Season, age, 
rs10741657  
1,25(OH)2D at baseline OC 0.46 0.004 (0.002, 0.007) 0.002 Season, 
rs10741657 
1,25(OH)2D at study-end NTx 0.31 −0.002 (−0.003, 4.4e-5) 0.056 BMI 
24,25(OH)2D at study-end NTx 0.68 −0.061 (−0.126, 0.004) 0.063 Ethnicity, 
gestational 
weight gain, 
rs10741657 
Free 25(OH)D at study-end NTx 0.30 −0.018 (−0.038, 0.001) 0.062 BMI 
Free 25(OH)D at study-end ALP 0.90 −0.011 (−0.018, −0.004) 0.004 BMI, education, 
infant weight, 
infant length, 
rs7041 
3-epi-25(OH)D3 at baseline ALP 0.92 −0.078 (−0.119, −0.037) 0.001 BMI, ethnicity, 
season, infant 
weight, infant 
length, mode of 
delivery 
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Table 3.2 (Continued)      
 
3-epi-25(OH)D3  
at study-end 
 
DPD/Cr 
 
0.56 
 
−0.040 (−0.075, −0.004) 
 
0.031 
 
Age, infant 
length 
3-epi-25(OH)D3  
at study-end 
ALP 0.49 −0.058 (−0.093, −0.023) 0.002 BMI 
Δ 3-epi-25(OH)D36 NTx 0.72 −0.104 (−0.020, −0.007) 0.037 BMI, 
rs10741657, 
rs7041, infant 
weight, infant 
head 
circumference 
 Fetal bone markers at delivery  
 
Δ 25(OH)D6 
 
OC 
 
0.83 
 
0.042 (0.015, 0.068) 
 
0.005 
 
BMI, gestational 
weight gain, 
rs10741657, 
rs7041 
24,25(OH)2D at study-end CTx 0.70 0.031 (0.007, 0.055) 0.018 BMI, ethnicity, 
gestational 
weight gain, 
infant weight, 
rs10741657, 
prestudy 
supplement use 
Free 25(OH)D at baseline CTx 0.53 0.008 (0.001, 0.015) 0.021 Gestational 
weight gain, 
infant weight, 
infant length, 
rs10741657  
1Data were derived using linear mixed models which controlled for covariates.    
2All biochemical markers of bone turnover were log(ln)-transformed except for fetal CTx.   
3None of these associations achieved statistical significance among nonpregnant women. 
4Influential covariates which achieved statistical significance (P < 0.05) were retained in the final 
model of each outcome. 
5Two intake levels of dietary choline of this study did not achieve a statistical significance, and 
consequently, were not included in any of the final models.  
6Calculated by subtracting baseline values from study-end values. 
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Effect of pregnancy on biochemical markers of bone turnover and their response through 
time  
Plasma intact parathyroid hormone 
 Pregnant women had lower (P = 0.005) iPTH concentrations than nonpregnant women at 
baseline (Figure 3.1A). Reproductive state did not interact with time (P = 0.533) to affect 
circulating iPTH concentrations. However, iPTH concentrations increased by a mean of 38% (P = 
0.054) among pregnant women throughout the study, but not among nonpregnant women whose 
concentrations remained stable (P = 0.594; Figure 3.1A). Similar to baseline, iPTH concentrations 
were 31% lower (P = 0.043) among pregnant women (18 pg/mL) than nonpregnant women (26 
pg/mL) at study-end after adjustment for covariates (reproductive state, time, and CYP2R1 
rs12794714) (Figure 3.1A). 
 
Plasma carboxy-terminal cross-linking telopeptide of type 1 collagen 
CTx concentrations were not different (P > 0.9) between pregnant and nonpregnant women 
at baseline (Figure 3.1B). Reproductive state interacted with time (P < 0.001) to influence 
circulating CTx response. Specifically, pregnant women experienced a mean 55% increase in CTx 
(P < 0.001) throughout the study period (Figure 3.1B), whereas no change (P > 0.9) in CTx was 
detected in nonpregnant women. Consequently, pregnant women had 50% higher (P = 0.003) CTx 
concentrations (0.61 ng/mL) than nonpregnant women (0.40 ng/mL) at study-end after adjustment 
for covariates (reproductive state and time) (Figure 3.1B). 
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Plasma amino-terminal cross-linking telopeptide of type 1 collagen  
Pregnant women had higher (P = 0.006) NTx concentrations than nonpregnant women at 
baseline (Figure 3.1C). Reproductive state interacted with time (P = 0.006) to affect circulating 
NTx concentrations, with a mean 28% increase (P < 0.001) observed among pregnant women 
(Figure 3.1C), but not among nonpregnant women (P = 0.459). Similar to baseline, NTx 
concentrations in pregnant women (62 ng/mL) were 150% higher (P < 0.001) than nonpregnant 
women (25 ng/mL) at study-end after adjustment for covariates (reproductive state, time, CYP2R1 
rs12794714, season, BMI, and education) (Figure 3.1C). 
 
Urinary deoxypyridinoline / creatinine  
Urinary DPD/Cr values were not different (P = 0.136) between pregnant and nonpregnant 
women at baseline (Figure 3.1D). Reproductive state interacted with time (P < 0.001) to influence 
DPD/Cr. Pregnant women exhibited a mean 59% increase (P < 0.001) in DPD/Cr, although no 
change (P > 0.9) was detected in nonpregnant women (Figure 3.1D). As a result, pregnant women 
showed approximately 100% higher (P < 0.001) DPD/Cr (8.6 nmol/mmol) than nonpregnant 
women (4.5 nmol/mmol) at study-end after adjustment for covariates (reproductive state and time) 
(Figure 3.1D). 
 
Plasma osteocalcin  
 Pregnant women had lower (P = 0.005) OC concentrations that nonpregnant women at 
baseline (Figure 3.1E). Reproductive state interacted with time (P = 0.007) to influence circulating 
OC concentrations. Specifically, nonpregnant women experienced a mean 50% reduction (P < 
0.001) in OC throughout the study period, whereas OC remained stable among pregnant women 
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(P = 0.331). At study-end, there was no difference (P = 0.267) between pregnant (4.7 ng/mL) and 
nonpregnant (5.9 ng/mL) women after adjustment for covariates (reproductive state and time) 
(Figure 3.1E). 
 
Serum alkaline phosphatase 
Pregnant women had higher (P < 0.001) ALP concentrations than nonpregnant women at 
baseline (Figure 3.1F). Reproductive state interacted with time (P < 0.001) to affect circulating 
ALP response. ALP concentrations among pregnant women more than doubled (P < 0.001) over 
the course of the study (Figure 3.1F), whereas nonpregnant women showed stable concentrations 
(P = 0.705). Similar to baseline, pregnant women (186 U/L) had 240% higher (P < 0.001) ALP 
concentrations than nonpregnant women (54 U/L) at study-end after adjustment for covariates 
(reproductive state, time, and GC rs7041) (Figure 3.1F). 
 
Albumin-adjusted Serum Calcium and Phosphorus 
Pregnant women showed higher (P < 0.001) albumin-adjusted serum calcium 
concentrations (Figure 3.1G) and non-different (P = 0.646) phosphorus concentrations (Figure 
3.1H) as compared to nonpregnant women at baseline. Reproductive state did not interact with 
time (P ≥ 0.202) to influence albumin-adjusted serum calcium and phosphorus concentrations. 
However, pregnant women experienced a significant increase (P = 0.002) in albumin-adjusted 
serum calcium through time (Figure 3.1G),whereas albumin-adjusted serum calcium remained 
stable (P > 0.452) among nonpregnant women. While no change (P = 0.545) in serum phosphorus 
occurred among pregnant women, a significant increase (P = 0.030) in phosphorus was detected 
in nonpregnant women over the course of the study (Figure 3.1H). Similar to baseline, pregnant 
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women showed higher (P < 0.001) albumin-adjusted serum calcium concentrations than 
nonpregnant women at study-end after adjustment for covariates (reproductive state and time) 
(Figure 3.1G), whereas phosphorus did not differ (P = 0.084) between the two groups after 
adjustment for covariates (reproductive state and time) (Figure 3.1H). 
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Figure 3.1. Biochemical markers of bone turnover in pregnant and nonpregnant women 
consuming equivalent and adequate amounts of vitamin D, calcium, and phosphorus for 10 weeks. 
Values are predicted means after adjusted for covariates. Baseline values are represented as open 
shapes, while study-end values are represented as closed shapes. Different letters (i.e., a > b > c) 
indicate significant differences (P < 0.05) in bone markers between pregnant and nonpregnant 
groups at each study time point. An asterisk (*) indicates a significant change (P < 0.05) in the 
concentrations of bone markers within each group throughout the study, and a long cross symbol 
(†) indicates a borderline significant change (P = 0.054). (A) iPTH, intact parathyroid hormone; 
(B) CTx, carboxy-terminal cross-linking telopeptide of type 1 collagen; (C) NTx, amino-terminal 
cross-linking telopeptide of type 1 collagen; (D) Urinary DPD/Creatinine, urinary 
deoxypyridinoline/creatinine; (E) OC, osteocalcin; (F) ALP, alkaline phosphatase; (G) Albumin-
adjusted serum calcium; (H) Phosphorus.  
 
 
Comparison of fetal bone markers to maternal markers  
 Fetal OC concentrations at delivery (33.5 ng/mL) were 6-7 times higher (P < 0.001) than 
OC concentrations in pregnant women at baseline (5.8 ng/mL) and study-end (4.7 ng/mL) (Figure 
3.2A). Similarly, fetal CTx concentrations (0.77 ng/mL) were 30-100% higher (P < 0.034) than 
CTx concentrations in pregnant women at baseline (0.39 ng/mL) and study-end (0.61 ng/mL) 
(Figure 3.2B).   
 
Figure 3.2. (A, B) Bone turnover markers, OC and CTx, in pregnant women (baseline and study-
end) and their fetuses (delivery). Values are means (95% CIs). Different letters (i.e., a > b > c) 
indicate significant differences (P < 0.05) in OC and CTx between pregnant women and their 
fetuses.  
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DISCUSSION 
To the best of our knowledge, this is the first controlled feeding study to assess associations 
of vitamin D biomarkers with bone turnover during pregnancy. Participants consumed equivalent 
amounts of vitamin D along with calcium and phosphorus which can influence bone metabolism 
during pregnancy (19,34). The intake levels of all essential nutrients aligned with, or exceeded, 
current dietary recommendations (1). Our findings show associations between several vitamin D 
biomarkers and a panel of biochemical markers of maternal and fetal bone metabolism. Moreover, 
our data suggest that achieving higher concentrations of maternal vitamin D biomarkers including 
25(OH)D (> 90 nmol/L) across the last third of pregnancy may be a nutritional strategy for 
reducing pregnancy-induced maternal bone loss. 
 
Higher maternal concentrations of vitamin D biomarkers are associated with reduced 
maternal bone resorption 
We found that increases in serum 25(OH)D across the third trimester of pregnancy were 
associated with decreases in bone turnover markers (i.e., DPD/Cr and OC). In addition, higher 
concentrations of 24,25(OH)2D, which rise in parallel with 25(OH)D, were associated with lower 
NTx concentrations among pregnant women at study-end (near term) although statistical 
significance was not achieved (P = 0.063). This latter finding is consistent with previous studies 
in vitamin D-replete animals showing reduced bone resorption during the administration of 
pharmacological doses of 24,25(OH)2D (35,36). Of note, free 25(OH)D (but not protein-bound 
25(OH)D) was negatively associated with PTH in pregnant women at baseline, suggesting that 
low concentrations of free 25(OH)D may increase PTH secretion, possibly resulting in greater 
calcium loss from maternal bone at the beginning of the third trimester. Furthermore, lower 
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concentrations of free 25(OH)D at study-end were also associated with higher study-end 
concentrations of the bone resorption marker NTx. Although 1,25(OH)2D was positively 
associated with DPD/Cr throughout the study period, it was also negatively related to NTx. In 
addition, higher 1,25(OH)2D concentrations were associated with higher OC concentrations at both 
baseline and study-end.  
Overall, data from these functional bone health outcomes suggest that higher 
concentrations of maternal vitamin D biomarkers including 25(OH)D (> 90 nmol/L) might reduce 
calcium mobilization from maternal bone. However, while this reduction may be of benefit to 
maternal bone, it raises questions as to the adequacy of calcium supply to the developing fetus. 
Notably, albumin-adjusted serum calcium concentrations increased throughout the third trimester 
of our pregnant participants, and this increase was not influenced by any of the biomarkers of 
vitamin D status even after adjustments. These findings suggest that net calcium transfer from the 
maternal to the fetal compartment was uncompromised by vitamin D-associated declines in 
maternal bone resorption. A recent randomized controlled trial in Iran that administered a high 
vitamin D dose (2,000 IU) throughout the third trimester (37) reported no difference in maternal 
bone measurements between the supplement and placebo groups. However, the supplementation 
group showed low serum 25(OH)D concentrations (mean of 45 nmol/L) over the course of the 
study, indicating that the high dose of vitamin D supplementation did not yield sufficient vitamin 
D status among the pregnant women. These data collectively suggest that concentrations of 
vitamin D biomarkers [e.g., 25(OH)D], rather than the assigned vitamin D dose, might be an 
important discriminatory factor when ascertaining the effects of maternal vitamin D on bone health. 
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Maternal vitamin D biomarkers are associated with fetal bone metabolism 
Increases in maternal serum 25(OH)D across the third trimester were associated with 
increases in fetal OC. This finding suggests that achieving higher maternal 25(OH)D 
concentrations during pregnancy may promote bone formation in fetal skeleton. Maternal 
25(OH)D readily crosses the placenta (38); thus greater transfer of 25(OH)D to the fetal 
compartment could enhance fetal OC synthesis by raising fetal 1,25(OH)2D which is known to 
stimulate OC production (39). Alternatively, because achieving higher maternal 25(OH)D 
concentrations was coincidentally associated with lower maternal OC levels among pregnant 
women in this study, it is also possible that maternal 25(OH)D has a putative a role in the 
transplacental movement of maternal OC, which has been shown to cross the placenta (40).  
In addition to bone formation, mineralization of the fetal skeleton encompasses bone 
resorption. In the present study, maternal free 25(OH)D and 24,25(OH)2D were positively 
associated with fetal CTx, a marker of bone resorption. Thus, a higher maternal vitamin D status 
appears to promote fetal bone turnover (i.e., bone formation + bone resorption) which may be 
favorable when mineralization of the fetal skeleton is accelerated. However, due to a lack of 
calcium and other bone resorption marker measurements in cord blood as well as amniotic fluid, 
we cannot exclude the possibility that higher fetal bone resorption may be indicating fetal 
hypocalcemia and fetal skeleton demineralization. Nonetheless, this appears unlikely within the 
context of this study because fetal demineralization resulting from elevated fetal bone resorption 
generally transpires secondary to diminished maternal calcium transfer. 
In contrast to the other vitamin D biomarkers, maternal 3-epi-25(OH)D3 did not show any 
relationship with bone markers in fetuses, suggesting that maternal 3-epi-25(OH)D3 may not 
influence fetal bone metabolism. Unlike 25(OH)D, 3-epi-25(OH)D3 may not readily cross the 
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placenta to the fetus, and consequently, would not participate in fetal bone development. Indeed, 
no significant correlation was detected between maternal and fetal 3-epi-25(OH)D3 in a recently 
published study (41). 
 Our findings of associations between maternal vitamin D biomarkers and fetal markers of 
bone metabolism appear to be inconsistent with two recent randomized controlled trials (42,43) 
which demonstrated no effects of maternal vitamin D3 supplementation (1,000 IU/d (43) and 200 
IU/d (42)) on fetal bone measurements as compared to a placebo group. The reasons for these 
inconsistencies are unclear but may be due to differences in the intake of bone-related nutrients. 
For example, dietary calcium was not reported in one study (43) and the supplementation group 
had very low vitamin D intake (234 IU/d from food and the supplement) in the other study (42). 
In addition, genetic variants that might alter bone metabolism were not assessed in either study 
which may obscure study findings. For example, in the present study, CYP2R1 rs10741657 A > G 
polymorphism emerged as the most common significant covariate in the linear mixed models 
examining associations between vitamin D biomarkers and maternal/fetal bone turnover markers. 
In addition, others have reported that polymorphisms in the VDR gene influenced changes in bone 
measurements among adolescent pregnant women consuming supplemental vitamin D and 
calcium (44). 
 
Pregnancy induced a net negative balance of bone metabolism even under conditions of 
sufficient intake of bone-related nutrients  
All of the bone resorption markers (i.e., CTx, NTx, and urinary DPD/Cr) increased by 28-
60% throughout the third trimester of pregnancy and were 50-150% higher than those of 
nonpregnant women consuming equivalent amounts of bone-related nutrients, even after 
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controlling for another confounding factors such as BMI, ethnicity/race, season, and vitamin D-
related genetic variants. In contrast, concentrations of the bone formation marker OC did not 
change among pregnant women, nor did it differ from those of nonpregnant women at study-end, 
which aligns with prior work (45–47). This finding of stable and non-different OC concentrations 
among pregnant women remained (P > 0.9) even after removing the effects of hemodilution by 
adjusting for albumin concentrations. Further, although ALP increased and remained higher 
among pregnant women, this increase is partly attributable to the placental contribution and may 
not be an accurate reflection of maternal bone formation. Overall, our findings are consistent with 
other longitudinal studies that have reported high levels of bone resorption among third-trimester 
women (45–48). 
In agreement with some (47,49) but not all (50,51) previous work, pregnant women 
maintained lower PTH concentrations than nonpregnant women throughout their third trimester. 
Moreover, although PTH is well-known for its role in stimulating the production of 1,25(OH)2D 
in nonpregnant state, 1,25(OH)2D was not associated (P ≥ 0.293) with PTH at any study time-
point among pregnant women. Taken together, the divergent relationship between these hormones 
supports prior work indicating that 1,25(OH)2D is not under the influence of PTH during 
pregnancy (52). 
 
Study limitations 
This feeding study provided a single dose of vitamin D and thus prohibited comparisons 
among dosing levels. In addition, the study sample size was relatively small and may have reduced 
the statistical power of our study. Finally, bone mass parameters, indicative of quantitative bone 
changes, were not obtained. 
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Conclusions 
Overall data from the present study suggest that higher concentrations of maternal vitamin 
D biomarkers including 25(OH)D (> 90 nmol/L) might have functional benefits for pregnant 
women by reducing maternal bone resorption without compromising fetal calcium supply. Large-
scale randomized controlled trials with higher doses of vitamin D supplementation are needed to 
confirm the potential functional benefits (i.e., less reduction in maternal bone mass) within the 
context of adequate dietary calcium and phosphorus intake. 
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Supplemental Table S3.1. Gestational and neonatal outcomes of the third-trimester pregnant 
women1  
  
 Pregnant women (n = 26) 
Choline intake (480 or 930 mg choline/d) 13 / 13 
Gestational age at birth (weeks) 40.0 [39.8 – 40.0] 
Gestational weight gain (kg) 15.4 [12.1 – 18.6] 
Mode of delivery (Vaginal / Caesarean Section, n)               19 / 5 
Parity (Primiparas / Multiparas, n)               12 / 14 
Season at birth (April–September / October–March, n)           18 / 4 
Infant gender (Boy / Girl, n)       19 / 7 
Infant birth weight (kg)       3.4 ± 0.3 
Infant head circumference (cm)        34.2 ± 1.1 
Infant length (cm)     50.8 [49.2 – 52.1] 
 
1Data are presented as mean±SDs for infant birth weight and infant head circumference; medians 
[IQRs] for gestational age at birth, gestational weight gain, and infant length; and sample size 
number.  
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AFTERWORD 
  Maternal vitamin D inadequacy, a global health problem, increases the risk of adverse 
pregnancy outcomes. Yet, many aspects of vitamin D metabolism and requirements in human 
pregnancy are poorly understood. My dissertation research, which experimentally controlled 
intakes of vitamin D and related nutrients, advances our fundamental understanding of vitamin D 
metabolism and requirements in three major ways.     
 First, the data showed that pregnant women had higher circulating vitamin D metabolites 
and other indicators of vitamin D status than nonpregnant women under dietary conditions of 
equivalent vitamin D intake. Of note, these differences remained after adjusting for several 
confounding factors, suggesting that pregnancy accommodates the demands for vitamin D by 
increasing the maternal circulating pool of vitamin D in a manner that is independent of dietary 
intake, season, BMI, and ethnicity/race. Second, the data provide evidence in support of an active 
role of the placenta in modulating maternal vitamin D metabolism and status. For example, 
numerous significant associations of circulating vitamin D metabolites with placental vitamin D 
metabolites and placental mRNA abundance of vitamin D machinery were observed. Moreover, 
the data from the HTR-8/SVneo cell culture model demonstrated for the first time an ability of 
human placental trophoblasts to produce and secrete 25(OH)D3, illustrating the placenta as a 
source of all forms of the major vitamin D metabolites [i.e., 25(OH)D, 1,25(OH)2D, and 
24,25(OH)2D]. Lastly, the data also showed that several of the vitamin D biomarkers were 
inversely associated with bone resorption markers among pregnant women who consumed 
adequate amounts of calcium and phosphorus. Importantly, these vitamin D-associated declines in 
maternal bone resorption were not accompanied by a fall in albumin-adjusted serum calcium 
concentrations, indicating that calcium delivery to fetus was not compromised.  
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 Overall, these data are anticipated to inform future establishment of vitamin D 
recommendations for pregnant women that promote optimal maternal health including bone 
protection. Additional studies are needed that administer higher or lower vitamin D intakes than 
the intake provided in this study and include a period of early pregnancy. 
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Pregnant Women 
Health History Questionnaire 
 
 
Demographic Information 
 
 
Date: _______________________________ 
     Month  Day  Year 
 
 
Name: ____________________________________________________________ 
 First    Last 
 
 
Phone  ___________________ _____________________      __________________ 
   Home           Cell       Email 
 
Address:   ________________________________________________________________ 
   
________________________________________________________________ 
   
________________________________________________________________ 
   
 
Age: _____    Date of Birth: __________________ 
        Mo.   Day  Year 
 
 
Education Completed: 
   ______High School Graduate ______Master’s Degree 
 
   ______Bachelor’s Degree  ______Doctoral Degree  
    
 
Present Work/Student Status: 
 
 ______Working Full-time  ______Full-time student 
 ______Working Part-time  ______Part-time student 
 ______Not Employed   ______Retired 
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Pregnancy Information 
 
Gestational Age at Present:   _________________ (weeks)    
 
Date of Last Menstrual Period:  _________________ (month/day/year) 
 
Due Date:     _________________ (month/day/year)    
 
 
Anthropometric Data 
 
Height (without shoes)    _______ 
 
Pre-Pregnancy weight (dressed with shoes)  _______ 
 
Current weight (dressed with shoes)   _______  
 
 
Medical History 
 
Indicate if you have had or currently have any of the following medical problems.   
Check all that apply: 
 
Yes No 
 
___ ___ Alcoholism 
 
___ ___ Cardiovascular Disease (Atherosclerosis / Heart Attack/Stroke) 
 
___ ___ Eye Problems (ie, glaucoma, cataracts, retinopathy) 
 
___ ___ Gall Bladder Disease 
 
___ ___ High Blood Cholesterol 
 
___ ___ High Blood Pressure 
 
___ ___ Intestinal Disorders 
 
___ ___ Kidney Disease 
 
___ ___ Liver Disease 
 
___ ___ Lung Disease 
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___ ___ Neurologic/Seizure Disorder 
 
___ ___ Obesity / Overweight 
 
___ ___ Thyroid Disease 
 
___ ___ Tumors / Cancer – List type: _________________ 
 
___ ___ Ulcers 
 
___ ___ Other – Specify: ____________________________________________ 
 
___ ___ Recent surgeries?  If yes, specify: ______________________________ 
 
 
 
Indicate the prescription/nonprescription medicines you currently use on a regular basis. 
Check all that apply: 
 
___ Allergy Medicines/Antihistamines  ___ Antacids 
 
___ Antibiotics     ___ Anti-arrhythmics 
 
___ Anti-inflammatory Agents (i.e. Ibuprofen) ___ Aspirin 
 
___ Asthma Medicines    ___ Beta Blockers 
 
___ Blood Pressure Medicines   ___ Blood Thinners 
 
___ Diabetes Medicines – Specify: ____________________________________ 
 
___ Diuretics     ___ Gout Medicines 
 
___ Heart Medicines – Specify: _______________________________________ 
 
___ Hormones – Specify: ____________________________________________ 
 
___ Seizure Medicines    ___ Thyroid Medicines 
 
___ Medicines interfering with folate metabolism – Specify: ________________ 
 
___ Other – Specify: ________________________________________________ 
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Supplement Use 
Indicate the supplements you currently use on a regular basis. 
Check all that apply. 
 
___ Prenatal Supplement  (name/brand)  
 
____________________________________________________ 
 
___ Multivitamin/Minerals  ___ Herbs 
 
___ Amino acids    ___ Ergogenic Aids (i.e., creatine) 
 
___ Other-Specify: __________________________________________________________ 
 
 
Activity Status 
 
What would best describe your activity level? 
 
____ Level 1: Usual daily activities 
____ Level 2: Some form of exercise (i.e., walking, dancing, riding a bike) at least 3 times per 
week 
____ Level 3: Vigorous exercise (i.e., singles tennis, running, aerobics, weight lifting) at least 
3 times/ week. 
 
 
Beverage Consumption 
 
Indicate the amount and frequency with which you consume the following at present: 
 
   Amt.  Never/   Occas.  Freq.  Daily 
   (each)  Rarely (5x/yr)  (2-3x/mo.) (2-3x/wk.) 
Beer   _____  _____   _____  _____  _____ 
Liquor   _____  _____   _____  _____  _____ 
Wine   _____  _____   _____  _____  _____ 
Wine Coolers  _____  _____   _____  _____  _____ 
Coffee   _____  _____   _____  _____  _____ 
Tea   _____  _____   _____  _____  _____ 
Soda             _____       _____             _____       _____       _____ 
 
 
 119 
Lactating Women 
Health History Questionnaire 
 
 
 
Demographic Information 
 
 
 
Date:  ____________________________________ 
  Month  Day  Year 
 
 
Name:  ____________________________________________________________ 
   First          Last 
 
 
Phone _________________  _________________     _________________________ 
  Home    Cell           Email 
 
Address:   ________________________________________________________________ 
   
________________________________________________________________ 
   
________________________________________________________________ 
   
Age:  _____    Date of Birth:  ___________________ 
         Mo.   Day    Year 
 
 
Education Completed: 
   ______High School Graduate ______Master’s Degree 
 
   ______Bachelor’s Degree  ______Doctoral Degree  
    
Present Work/Student Status: 
 
 ______Working Full-time  ______Full-time student 
 ______Working Part-time  ______Part-time student 
 ______Not Employed   ______Retired 
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Pregnancy Information 
 
Due Date:     _________________ (month/day/year)    
 
Delivery Date:    _________________ (month/day/year) 
 
Health Insurance Provider:  __________________________________________ 
 
Total Weight Gained During Pregnancy: ____________________________________________ 
 
Complications During Pregnancy:   _______ Yes  _______No 
 
If yes, describe: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
Complications During Labor:  _______Yes   ________No 
 
If yes, describe: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
 
 
Newborn Information 
 
Date of Delivery:   _______________________________ 
   Month  Day  Year 
 
 
Mode of Delivery (i.e., vaginal or C-section): ________________________________ 
 
Gestational Age:   _______________________________ 
 
Length:   ______________________________ 
 
Weight:  ______________________________ 
 
Head Circumference: ______________________________ 
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Anthropometric Data 
 
Height (without shoes)    _______ 
 
Pre-Pregnancy weight (dressed with shoes)  _______ 
 
Current weight (dressed with shoes)   _______  
 
 
Medical History 
 
Indicate if you have had or currently have any of the following medical problems.   
Check all that apply: 
 
Yes No 
 
___ ___ Alcoholism 
 
___ ___ Cardiovascular Disease (Atherosclerosis / Heart Attack/Stroke) 
 
___ ___ Eye Problems (ie, glaucoma, cataracts, retinopathy) 
 
___ ___ Gall Bladder Disease 
 
___ ___ High Blood Cholesterol 
 
___ ___ High Blood Pressure 
 
___ ___ Intestinal Disorders 
 
___ ___ Kidney Disease 
 
___ ___ Liver Disease 
 
___ ___ Lung Disease 
 
___ ___ Neurologic/Seizure Disorder 
 
___ ___ Obesity / Overweight 
 
___ ___ Thyroid Disease 
 
___ ___ Tumors / Cancer – List type: _________________ 
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___ ___ Ulcers 
 
___ ___ Other – Specify: ____________________________________________ 
 
___ ___ Recent surgeries?  If yes, specify: ______________________________ 
 
 
 
 
Indicate the prescription/nonprescription medicines you currently use on a regular basis. 
Check all that apply: 
 
 
___ Allergy Medicines/Antihistamines  ___ Antacids 
 
___ Antibiotics     ___ Anti-arrhythmics 
 
___ Anti-inflammatory Agents (i.e. Ibuprofen) ___ Aspirin 
 
___ Asthma Medicines    ___ Beta Blockers 
 
___ Blood Pressure Medicines   ___ Blood Thinners 
 
___ Diabetes Medicines – Specify: ____________________________________ 
 
___ Diuretics     ___ Gout Medicines 
 
___ Heart Medicines – Specify: _______________________________________ 
 
___ Hormones (ie, birth control bills) – Specify: 
__________________________________________ 
 
___ Seizure Medicines    ___ Thyroid Medicines 
 
___ Medicines interfering with folate metabolism – Specify: ________________ 
 
___ Other – Specify: ________________________________________________ 
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Supplement Use 
 
 
Indicate the supplements you currently use on a regular basis. 
Check all that apply. 
 
___ Prenatal Supplement  (name/brand)  
 
____________________________________________________________________ 
 
___ Multivitamin/Minerals  ___ Herbs 
 
___ Amino acids    ___ Ergogenic Aids (i.e., creatine) 
 
___ Other-Specify:  
 
_____________________________________________________________________ 
 
 
Activity Status 
 
What would best describe your activity level? 
____ Level 1: Usual daily activities 
____ Level 2: Some form of exercise (i.e., walking, dancing, riding a bike) at least 3 times per 
week 
____ Level 3: Vigorous exercise (i.e., singles tennis, running, aerobics, weight lifting) at least 
3 times/ week. 
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Non-Pregnant Women 
Health History Questionnaire 
 
 
 
Demographic Information 
 
Date:  _____________________________________ 
  Month  Day  Year 
 
 
Name:  ____________________________________________________________ 
   First           Last 
 
 
Phone  ________________       _________________  ______________________ 
  Home    Cell       Email 
 
Address:   ________________________________________________________________ 
   
________________________________________________________________ 
   
________________________________________________________________ 
   
Age:  _____    Date of Birth:  ______________________ 
         Mo.     Day Year 
 
 
Education Completed: 
   ______High School Graduate ______Master’s Degree 
 
   ______Bachelor’s Degree  ______Doctoral Degree  
    
 
Present Work/Student Status: 
 
 ______Working Full-time  ______Full-time student 
 ______Working Part-time  ______Part-time student 
 ______Not Employed   ______Retired 
 
 
Number of Children:  ______________ 
 
 
Number of pregnancies: _____________ 
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Anthropometric Data 
 
 
Height (without shoes)   _______ 
 
Current weight (dressed with shoes)  _______  
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Medical History 
 
 
Indicate if you have had or currently have any of the following medical problems.   
Check all that apply: 
 
Yes No 
 
___ ___ Alcoholism 
 
___ ___ Cardiovascular Disease (Atherosclerosis / Heart Attack/Stroke) 
 
___ ___ Eye Problems (ie, glaucoma, cataracts, retinopathy) 
 
___ ___ Gall Bladder Disease 
 
___ ___ High Blood Cholesterol 
 
___ ___ High Blood Pressure 
 
___ ___ Intestinal Disorders 
 
___ ___ Kidney Disease 
 
___ ___ Liver Disease 
 
___ ___ Lung Disease 
 
___ ___ Neurologic/Seizure Disorder 
 
___ ___ Obesity / Overweight 
 
___ ___ Thyroid Disease 
 
___ ___ Tumors / Cancer – List type: _________________ 
 
___ ___ Ulcers 
 
___ ___ Other – Specify: ____________________________________________ 
 
___ ___ Recent surgeries?  If yes, specify: ______________________________ 
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Indicate the prescription/nonprescription medicines you currently use on a regular basis. 
Check all that apply: 
 
 
___ Allergy Medicines/Antihistamines  ___ Antacids 
 
___ Antibiotics     ___ Anti-arrhythmics 
 
___ Anti-inflammatory Agents (i.e. Ibuprofen) ___ Aspirin 
 
___ Asthma Medicines    ___ Beta Blockers 
 
___ Blood Pressure Medicines   ___ Blood Thinners 
 
___ Diabetes Medicines – Specify: ____________________________________ 
 
___ Diuretics     ___ Gout Medicines 
 
___ Heart Medicines – Specify: _______________________________________ 
 
___ Hormones – Specify: ____________________________________________ 
 
___ Seizure Medicines    ___ Thyroid Medicines 
 
___ Medicines interfering with folate metabolism – Specify: ________________ 
 
___ Other – Specify: ________________________________________________ 
 
 
 
Supplement Use 
 
Indicate the supplements you currently use on a regular basis. 
Check all that apply. 
 
___ Multivitamin/Minerals  ___ Herbs 
 
___ Amino acids    ___ Ergogenic Aids (i.e., creatine) 
 
___ Other-Specify:  
 
_____________________________________________________________________ 
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Activity Status 
 
 
What would best describe your activity level? 
____ Level 1: Usual daily activities 
____ Level 2: Some form of exercise (i.e., walking, dancing, riding a bike) at least 3 times per 
week 
____ Level 3: Vigorous exercise (i.e., singles tennis, running, aerobics, weight lifting) at least 
3 times/ week. 
 
 
 
Beverage Consumption 
 
Indicate the amount and frequency with which you consume the following: 
 
   Amt.  Never/   Occas.  Freq.  Daily 
   (each)  Rarely (5x/yr)  (2-3x/mo.) (2-3x/wk.) 
Beer   _____  _____   _____  _____  _____ 
Liquor   _____  _____   _____  _____  _____ 
Wine   _____  _____   _____  _____  _____ 
Wine Coolers  _____  _____   _____  _____  _____ 
Coffee   _____  _____   _____  _____  _____ 
Tea   _____  _____   _____  _____  _____ 
Soda   _____  _____   _____  _____  _____ 
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Cornell University  
Informed Consent for Research Involving Human Study Participants 
 
 
You are being invited to participate in a research study. This form is designed to 
provide you with information about this study. The Principal Investigator or 
representative will describe this study to you and answer any of your questions.   
 
Project Title:  
Effect of maternal choline intake on maternal/fetal biomarkers of choline status  
 
Investigators: 
Marie Caudill, PhD, RD; Associate Professor, Division of Nutritional Sciences, Cornell 
University 
Eva Pressman, MD. Director of Obstetrics and Maternal-Fetal Medicine, Department of 
Obstetrics and Gynecology, University of Rochester School of Medicine, Rochester, New York 
Richard Canfield, PhD. Research Associate, Division of Nutritional Sciences, Cornell University 
Barbara Strupp, PhD. Professor, Division of Nutritional Sciences, Cornell University 
Srisatish Devapatla, MD. Director, Special Care Nursery, Chairman- Dept. of Pediatrics, Cayuga 
Medical Center at Ithaca, Ithaca, New York. 
Sandy Saintonge, MD. Assistant Professor of Clinical Public Health and Clinical Pediatrics, 
Weill Cornell Medical College, Attending Physician, New York Hospital Queens, Department of 
Emergency Medicine 
Cydne Perry, PhD. Post-doctoral Associate, Division of Nutritonal Sciences, Cornell University 
 
What the study is about:  
Choline, a nutrient found in the diet (i.e., eggs, nuts, and beef), was recently 
recognized as a required nutrient for humans.  The recommended dietary intake 
level for pregnant women is 450 mg/d. However, at present, it is not known 
whether this amount is optimal for pregnant women.   
Thus, this study seeks to assess the effect of pregnancy on choline status and to 
examine whether the current recommended dietary intake, 450 mg/d, is enough to 
optimize choline status during pregnancy.   
 
 
 
 
Consent, Pregnant Women 
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There is evidence from animal studies that excess choline consumed by the mother 
during pregnancy may have long lasting beneficial effects on the memory and 
attention of the newborn. However, no study has examined this in humans.  
Thus, this study seeks to assess the effect of extra choline (450 mg/d) for a total 
choline intake of 900 mg/d during pregnancy on learning, attention and memory in 
the infant.  The choline intake of 900 mg/d is an amount that can be obtained by 
the diet and is well below the upper level of tolerance, 3500 mg/d. 
 
There is evidence that choline status affects folate (another essential nutrient) and 
vice versa. Thus, this study seeks to examine the relationship between choline and 
folate status.
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What we will ask you to do:   
Screening Phase: 
First, it is necessary to determine whether you meet the inclusion criteria of this 
study.  This process will take up to 1 hour.  The inclusion criteria are as follows:   
 I am pregnant  (non-pregnant women are also eligible for the study in order 
to provide us with a control group) 
 I have not entered my third trimester (i.e., wk 27) 
 I am between 21 and 40 years of age. 
 I eat meat and other animal products 
 I am not a current smoker. 
 I am not using recreational drugs  
 I am not drinking alcoholic beverages  
 I am healthy 
 I do not have gestational diabetes 
 I do not have anemia. 
 I do not have kidney or liver problems. 
 I am not chronically taking medication that affects liver function. 
 I had a body mass index (BMI) < 34 as my pre-pregnancy weight 
During the screening phase, you will have your blood drawn (~ 4 tablespoons) 
which will be used to assess your health status and measure select 
vitamins/nutrients.  DNA will also be obtained from your blood in order to 
investigate the effect of nutrients for people of different genetic make-up.  You 
will also complete a health history questionnaire.   
 
Dietary Intervention Phase  
If you meet the required criteria, you will be invited to participate in a twelve week 
feeding study.  Throughout this study you will consume a normal mixed diet 
consisting of breakfast, lunch, dinner and snacks.  You will consume at least one 
meal per day (breakfast, lunch or dinner) in the human metabolic research unit 
located at Cornell University.  The other meals will be provided as takeout meals.  
You will also consume a prenatal vitamin/mineral supplement to ensure that you 
are meeting the recommended dietary intake levels for pregnant women of all the 
essential nutrients.  In addition, you will be randomized to a choline supplement to 
 132 
achieve total choline intakes of 450 or 900 mg/d.  To increase the study’s validity, 
the level of choline intake to which you are assigned (i.e., 450 or 900 mg/d) will 
not be disclosed.  
 
To help us better understand choline requirements and use during pregnancy, a 
small portion of the choline will be labeled from week 6 to 12.  This label 
(marker) is safe and has been used many times in studies involving babies, young 
children and pregnant women.  
 
It is important that you eat all of the food that we give you and that you eat nothing 
else outside of the study food. You will be weighed every week and extra 
food/beverages will be provided as necessary to ensure appropriate weight gain (~ 
1 pound per week).   
 
Blood will be taken by a trained phlebotomist (i.e., a person that is trained to draw 
blood) before the start of the study and at weeks 3, 6, 9, 10 and 12.  The blood will 
be used to analyze how choline intake, folate intake and/or pregnancy influences 
biomarkers of status. Also we will use the DNA obtained from the blood to analyze 
how genetic differences influence the use of choline and/or folate.  In addition, 
you will be required to collect your urine over a 24 hour period at the beginning of 
the study (week 0) and at weeks 6, 9, and 12.   
 
Time Between End of Dietary Intervention Phase and Delivery 
We request that you continue on the choline supplement that you consumed during 
the intervention study (ie, 100 or 500 mg/d) until you delivery the baby.  This is 
an estimated time of 1 week.  We will provide the choline supplement on a weekly 
basis. 
 
At Delivery 
We intend to obtain a final blood sample from you and from the umbilical cord 
when you deliver the baby.  This blood will be used to measure your choline and 
folate status as well as that of the baby (i.e., umbilical cord).  We will also use the 
cord blood to extract DNA to provide information on the influence of genetic 
differences on choline/folate status in your baby. In addition, we intend to retain 
the placenta which is normally discarded after the delivery of your baby.  Your 
placenta will be used to examine how choline intake influences the expression of 
relevant genes as well as choline utilization.  Lastly, we intend to ask you a few 
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questions (i.e., less than 5 minutes of your time) about your delivery and the baby’s 
height and weight (included in your informational packet).   
 
Samples obtained during your participation on this study may be used by the 
investigators (or collaborators) for the purposes of learning more about other 
nutrients (ie., vitamin D and biotin) and how genetic differences affect 
requirements for these nutrients. 
It is possible that other investigators will have access to your blood samples (including DNA), 
placental tissue, and urine samples; however, the samples will be de-identified (ie, no names will 
be used). 
 
Cognitive Testing of Infant 
We would like to perform cognitive tests that assess your infant’s attention and 
memory when he/she is three, six, nine and twelve months of age.  These tests will 
measure your child’s eye movements to changes in pictures/images. Feeding your 
baby between tests is fine.  These tests are non-invasive. Each test is 
approximately 5-10 minute and will take up to 30 minutes total.
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Risks and benefits:  
We foresee minimal risks as part of your participation in this study. The choline 
dosage of 450 mg/d is the recommended amount for pregnant women and is 
considered to be adequate. The choline dosage of 900 mg/d is considered to be safe 
(Institute of Medicine, National Academy of Science) and falls within the range of 
choline intake consumed by the general population.  None-the-less, we will 
monitor your health status as you progress through this study.  Specifically we 
will  obtain a blood chemistry profile and a complete blood count at weeks 0, 3, 6, 
9 and 12.  These tests provide information on your blood lipids, liver and kidney 
function, and iron status.  We will also take your blood pressure on a weekly 
basis. Should any problems be identified, we will refer you to your physician who 
will advise on your continuing to participate in this study.  
 
 
As with any blood draw, it is also possible that you will experience some dizziness, 
ill-feeling and bruising during/after the blood draw.  In addition, having blood 
samples taken always includes a certain low risk of infection.  To minimize this 
risk,  blood will be drawn by a trained phlebotomist at the human metabolic 
research unit while you are lying down.   
 
 
There are no established direct benefits to you or your baby. From this study we 
hope to draw conclusions regarding the optimal intake levels of choline and folate 
in pregnant women, potentially benefiting the health of other women and children. 
 
In the event that you should be injured in the course of this research study, you will 
be provided with necessary medical care in Cayuga Medical Center At Ithaca.  
This statement does not mean that either such medical care or hospitalization, if 
necessary, will be free of charge. 
 
Compensation:  
Week of Study Payment 
1 $50 
2 $60 
3 $70 
4 $80 
5 $100 
6 $120 
7 $140 
8 $160 
9 $180 
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10 $200 
11 $220 
12 $240 
 
You will be paid the dollar amounts indicated above in two allotments ($480 at 
week 6 and $1140 at week 12) for a total of $1620. Should you stop participating 
in the study, you will be compensated for the time you have spent on the study.   
 
You will also be compensated for the blood and information obtained at delivery 
($100) and for each cognitive evaluation session ($50 per session x 4 sessions for a 
total of $200).   
 
Taking part is voluntary:  
Your participation in this study is completely voluntary. If you decide to take part, 
you are free to withdraw at any time; however you will not be eligible to receive 
monetary compensation after ending the study.  You will be able to keep the 
money you have earned up to that point.  
The results of your blood tests, the genotyping and your child's cognitive tests 
will be kept confidential.  
In any sort of report we make public, we will not include any information that will 
make it possible to identify you. Research records will be kept in a locked file; 
only the researchers will have access to the records. We will need to videotape the 
infant’s face in order to analyze reaction times based on the infant’s eye 
movements.  Only the researchers will have access to the videotape.  Upon the 
conclusion of the data analysis, the videotape will be destroyed (by September 
2015). 
 
If you have questions: The main researcher conducting this study is Professor 
Marie Caudill. Please ask any questions you have now. If you have questions later, 
you may contact Marie Caudill at mac379@cornell.edu or at 607-254-7456.  
Should you contact Professor Caudill via email, please be aware that there is a chance that your 
answers could be read by a third party as internet and email transmissions are neither private or 
secure. 
If you have any questions or concerns regarding your rights as a subject in this 
study, you may contact the Institutional Review Board (IRB) for human study 
participants at 607-255-5138 or access their website at http://www.irb.cornell.edu. 
You may also report your concerns or complaints anonymously through 
Ethicspoint or by calling toll free at 1-866-293-3077. Ethicspoint is an independent 
organization that serves as a liaison between the University and the person 
bringing the complaint so that anonymity can be ensured. 
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You will be given a copy of this form to keep for your records.   
 
Statement of Consent: I have read the above information, and have received 
answers to any questions I asked. I consent to take part in the study.  
 
Your Signature ____________________________  Date _____________ 
Study Representative Signature ____________________ Date _____________ 
 
In addition to agreeing to participate, I also consent to having my child's cognitive 
function assessed and to having these activities videotaped during the session. 
 
Your Signature ________________________________  Date _____________ 
Study Representative Signature ____________________ Date _____________ 
 
This consent form will be kept by the researcher for at least five years beyond the 
end of the study and was approved by University of Cornell’s Institutional Review 
Board for Use of Human Study Participants  on June 5 2008 and by Cayuga’s 
Medical Center’s Review Board for Use of Human Study Participants on October 
16, 2008. 
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Cornell University  
Informed Consent for Research Involving Human Study Participants 
 
 
You are being invited to participate in a research study. This form is designed to 
provide you with information about this study. The Principal Investigator or 
representative will describe this study to you and answer any of your questions.   
 
Project Title:  
Effect of maternal choline intake on maternal/fetal biomarkers of choline status  
 
Investigators: 
Marie Caudill, PhD, RD; Associate Professor, Division of Nutritional Sciences, Cornell 
University 
Eva Pressman, MD. Director of Obstetrics and Maternal-Fetal Medicine, Department of 
Obstetrics and Gynecology, University of Rochester School of Medicine, Rochester, New York 
Richard Canfield, PhD. Research Associate, Division of Nutritional Sciences, Cornell University 
Barbara Strupp, PhD. Professor, Division of Nutritional Sciences, Cornell University 
Srisatish Devapatla, MD. Director, Special Care Nursery, Chairman- Dept. of Pediatrics, Cayuga 
Medical Center at Ithaca, Ithaca, New York. 
Sandy Saintonge, MD. Assistant Professor of Clinical Public Health and Clinical Pediatrics, 
Weill Cornell Medical College, Attending Physician, New York Hospital Queens, Department of 
Emergency Medicine 
Cydne Perry, PhD. Postdoctoral Research Associate, Division of Nutritonal Sciences, Cornell 
University 
 
What the study is about:  
Choline, a nutrient found in the diet (i.e., eggs, milk, and beef), was recently 
recognized as a required nutrient for humans.  However, at present, the amount of 
choline required during pregnancy and lactation is unknown.  Current dietary 
intakes in the general population range from ~ 100 to 1000 mg/d with an average 
intake of 300 mg/d.   In 1998, an “Adequate Intake” level for choline of 425, 450 
and 550 mg/d was established for non-pregnant, pregnant and lactating women 
respectively.  However, these estimates probably exceed actual requirements 
given that habitual choline intake levels in healthy populations are ~ 300 mg/d.         
 
Consent, Lactating Women 
 138 
There is evidence from animal studies that extra choline consumed by the mother 
during and after pregnancy may have long lasting beneficial effects on the memory 
and attention of the newborn.  However, no study has examined this in humans.  
 
Thus, this study seeks to examine choline metabolism (i.e., use) and requirements 
in pregnant and lactating women.  In addition, it seeks to assess whether higher 
choline intakes improve biomarkers of choline status (i.e., increase blood 
concentrations).   
 
Finally, there is evidence that choline status affects folate (another essential 
nutrient) and vice versa.  Thus, this study seeks to examine the relationship 
between choline and folate status.
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What we will ask you to do:   
Screening Phase: 
First, it is necessary to determine whether you meet the inclusion criteria of this 
study.  This process will take up to 1 hour.  The inclusion criteria are as follows:   
 I am a lactating mom who plans to exclusively breast feed for the duration of 
the study (ie, the next 10 weeks).   
 I can begin the feeding study at the start of my fifth week of lactation. 
 I am between 21 and 40 years of age. 
 I eat meat and other animal products. 
 I am not a current smoker. 
 I am not using recreational drugs.  
 I am not drinking alcoholic beverages.  
 I am healthy. 
 I do not have kidney or liver problems. 
 I am not chronically taking medication that affects liver function. 
During the screening phase, you will have your blood drawn (~ 4 tablespoons) 
which will be used to assess your health status and measure select 
vitamins/nutrients.  DNA will also be obtained from your blood in order to 
investigate the effect of nutrients for people of different genetic make-up.  You 
will also complete a health history questionnaire.   
 
Dietary Intervention Phase  
If you meet the required criteria, you will be invited to participate in a ten week 
feeding study.  Throughout this study you will consume a normal mixed diet 
consisting of breakfast, lunch, dinner and snacks.  You will consume at least one 
meal every Monday, Wednesday, and Friday (breakfast, lunch or dinner) in the 
human metabolic research unit located at Cornell University.  The other meals 
will be provided as takeout meals.  You will also consume a prenatal 
vitamin/mineral supplement to ensure that you are meeting the recommended 
dietary intake levels for lactating women of all the essential nutrients.   
 
The study diet provides 350 mg/d choline and contains food  items that are 
significant sources of choline (i.e., eggs, beef, and milk).  In addition, you will be 
randomized to a choline supplement to achieve total choline intakes of 450 or 900 
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mg/d.  To increase the study’s validity, the level of choline intake to which you 
are assigned (i.e., 450 or 900 mg/d) will not be disclosed.  
 
To help us better understand choline requirements and use during lactation, a small 
portion of the choline will be labeled from study week 6 to 10.  This label 
(marker) is safe and has been used many times in studies involving babies, young 
children and pregnant / lactating women.  
 
It is important that you eat all of the food that we give you and that you eat nothing 
else outside of the study food. You will be weighed every week and extra 
food/beverages will be provided as necessary to ensure that calorie needs are being 
met. 
 
Blood will be taken by a trained phlebotomist (i.e., a person that is trained to draw 
blood) before the start of the study and at weeks 3, 6, 9, and 10.  The blood will be 
used to analyze how choline intake, folate intake and/or lactation influences 
biomarkers of status. Also we will use the DNA obtained from the blood to analyze 
how genetic differences influence the use of choline and/or folate.   
In addition, you will be required to collect your urine over a 24 hour period and to 
provide a breast milk sample at the beginning of the study (week 0) and at weeks 3, 
6, 9 and 10.   The breast milk will be expressed completely from one breast 
(either right or left) at the beginning of the second feeding time (ie, 10 am).  All 
supplies/materials needed for this expression will be provided.  Samples obtained 
during your participation on this study may be used by the investigators (or 
collaborators) for the purposes of learning more about other nutrients (ie., vitamin 
D and biotin) and how genetic differences affect requirements for these nutrients. 
It is possible that other investigators will have access to your blood samples (including DNA) 
and urine samples; however, the samples will be de-identified (ie, no names will be used). 
 
Cognitive Testing of Infant 
We would like to perform cognitive tests that assess your infant’s attention and 
memory when he/she is three, six, nine and twelve months of age.  These tests will 
measure your child’s eye movements to changes in pictures/images.  Feeding your 
baby between tests is fine.  These tests are non-invasive. Each test is 
approximately 5-10 minutes and will take up to 30 minutes total. 
Risks and benefits:  
We foresee minimal risks as part of your participation in this study.  The choline 
dose of 450 mg/d is below the “adequate intake” level of 550 mg/d; however, it is 
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above the average intake level of 300 mg/d consumed by the general population.  
In addition, the 450 mg/d choline intake level in this study is comprised of dietary 
choline obtained from a normal mixed diet (i.e., 350 mg/d) and supplemental 
choline (100 mg/d). The choline dosage of 900 mg/d is considered to be safe 
(Institute of Medicine, National Academy of Science) and falls within the upper 
range of choline intake consumed by the general population.  None-the-less, we 
will monitor your health status as you progress through this study.  Specifically 
we will  obtain a blood chemistry profile and a complete blood count at weeks 0, 
3, 6, 9 and 10.  These tests provide information on your blood lipids, liver and 
kidney function, and iron status.  We will also take your blood pressure on a 
weekly basis. Should any problems be identified, we will refer you to your 
physician who will advise on your continuing to participate in this study.  
 
 
As with any blood draw, it is also possible that you will experience some dizziness, 
ill-feeling and bruising during/after the blood draw.  In addition, having blood 
samples taken always includes a certain low risk of infection.  To minimize this 
risk,  blood will be drawn by a trained phlebotomist at the human metabolic 
research unit while you are lying down.   
 
 
There are no established direct benefits to you or your baby. From this study we 
hope to draw conclusions regarding the optimal intake levels of choline and folate 
in lactating women, potentially benefiting the health of other women and children. 
 
 
Compensation:  
Week of Study Payment 
1 $50 
2 $60 
3 $70 
4 $80 
5 $100 
6 $120 
7 $140 
8 $160 
9 $200 
10 $220 
 
You will be paid the dollar amounts indicated above in two allotments ($360 at 
week 5 and $840 at week 10) for a total of $1200. Should you stop participating in 
the study, you will be compensated for the time you have spent on the study.   
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You will also be compensated for each cognitive evaluation session ($50 per 
session x 4 sessions for a total of $200).   
 
Taking part is voluntary:  
Your participation in this study is completely voluntary. If you decide to take part, 
you are free to withdraw at any time; however you will not be eligible to receive 
monetary compensation after ending the study.  You will be able to keep the 
money you have earned up to that point.  
The results of your blood tests, the genotyping and your child's cognitive tests 
will be kept confidential.  
In any sort of report we make public, we will not include any information that will 
make it possible to identify you. Research records will be kept in a locked file; 
only the researchers will have access to the records. We will need to videotape the 
infant’s face in order to analyze reaction times based on the infant’s eye 
movements.  Only the researchers will have access to the videotape.  Upon the 
conclusion of the data analysis, the videotape will be destroyed (by September 
2015). 
 
If you have questions: The main researcher conducting this study is Professor 
Marie Caudill. Please ask any questions you have now. If you have questions later, 
you may contact Marie Caudill at mac379@cornell.edu or at 607-254-7456.  
Should you contact Professor Caudill via email, please be aware that there is a chance that your 
answers could be read by a third party as internet and email transmissions are neither private or 
secure. 
If you have any questions or concerns regarding your rights as a subject in this 
study, you may contact the Institutional Review Board (IRB) for human study 
participants at 607-255-5138 or access their website at http://www.irb.cornell.edu. 
You may also report your concerns or complaints anonymously through 
Ethicspoint or by calling toll free at 1-866-293-3077. Ethicspoint is an independent 
organization that serves as a liaison between the University and the person 
bringing the complaint so that anonymity can be ensured. 
 
You will be given a copy of this form to keep for your records.   
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Statement of Consent: I have read the above information, and have received 
answers to any questions I asked. I consent to take part in the study.  
 
Your Signature ____________________________  Date _____________ 
Study Representative Signature ____________________ Date _____________ 
 
In addition to agreeing to participate, I also consent to having my child's cognitive 
function assessed and to having these activities videotaped during the session. 
 
Your Signature ________________________________  Date _____________ 
Study Representative Signature ____________________ Date _____________ 
 
This consent form will be kept by the researcher for at least five years beyond the 
end of the study and was approved by University of Cornell’s Institutional Review 
Board for Use of Human Study Participants  on October 15, 2008. 
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Cornell University 
Informed Consent for Research Involving Human Study Participants 
 
 
You are being invited to participate in a research study. This form is designed to 
provide you with information about this study. The Principal Investigator or 
representative will describe this study to you and answer any of your questions.   
 
Project Title:  
Effect of maternal choline intake on maternal/fetal biomarkers of choline status  
 
Investigators: 
Marie Caudill, PhD, RD; Associate Professor, Division of Nutritional Sciences, Cornell 
University 
Eva Pressman, MD. Director of Obstetrics and Maternal-Fetal Medicine, Department of 
Obstetrics and Gynecology, University of Rochester School of Medicine, Rochester, New York 
Richard Canfield, PhD. Research Associate, Division of Nutritional Sciences, Cornell University 
Barbara Strupp, PhD. Professor, Division of Nutritional Sciences, Cornell University 
Srisatish Devapatla, MD. Director, Special Care Nursery, Chairman- Dept. of Pediatrics, Cayuga 
Medical Center at Ithaca, Ithaca, New York 
 
Sandy Saintonge, MD. Assistant Professor of Clinical Public Health and Clinical Pediatrics, 
Weill Cornell Medical College, Attending Physician, New York Hospital Queens, Department of 
Emergency Medicine 
Cydne Perry, PhD. Postdoctoral Research Associate, Division of Nutritonal Sciences, Cornell 
University 
 
What the study is about:  
This study seeks to provide data about nutrient requirements / utilization during 
pregnancy (see below).  You are being invited for possible participation in this 
study in order to examine choline requirements/use in non-pregnant women and to 
serve as a control for the pregnant women. 
 
Choline, a nutrient found in the diet, was recently recognized as a required nutrient 
for humans.  The recommended dietary intake level for non-pregnant and pregnant 
women is 425 or 450 mg/d, respectively. However, at present, it is not known 
whether 450 mg/d is enough to maintain choline status in pregnant women.   
 
Consent, Nonpregnant Women 
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Thus, this study seeks to assess the effect of pregnancy on choline status and to 
examine whether the current recommended dietary intake, 450 mg/d, is enough to 
maintain choline status during pregnancy. Your participation in this study will 
enable us to compare your choline status to that of a pregnant woman and in doing 
so assess the effect of pregnancy on choline status. 
 
It is possible that choline affects the use of folate, another essential nutrient and 
vice versa.    Thus, this study seeks to examine the relationship between choline 
and folate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 146 
What we will ask you to do:   
Screening Phase: 
First, it is necessary to determine whether you meet the inclusion criteria of this 
study.  This process will take up to 1 hour.  The inclusion criteria are as follows:   
 I am not pregnant or lactating 
 I am between 21 and 40 years of age 
 I eat meat and other animal products 
 I am not a current smoker. 
 I am not using recreational drugs  
 I am willing to refrain from drinking alcoholic beverages during the 12-week 
study period  
 I am healthy 
 I do not have anemia. 
 I do not have kidney or liver problems. 
 I am not chronically taking medication that affects liver function. 
 I have a body mass index (BMI) < 34 
During the screening phase, you will have your blood drawn (~ 4 tablespoons) 
which will be used to assess your health status and measure select 
vitamins/nutrients.  DNA will also be obtained from your blood in order to 
investigate the effect of nutrients for people of different genetic make-up.  You 
will also complete a health history questionnaire. 
 
Study Phase  
If you meet the required criteria, you will be invited to participate in a twelve week 
feeding study.  Throughout this study you will consume a normal mixed diet 
consisting of breakfast, lunch, dinner and snacks.  You will consume at least one 
meal per day (breakfast or dinner) in the human metabolic research unit located at 
Cornell University.  The other meals will be provided as takeout meals.  You will 
also consume a customized vitamin/mineral supplement to ensure that you are 
meeting the recommended dietary levels for pregnant (and non-pregnant) women 
of all the essential nutrients.  In addition, you will be randomized to a choline 
supplement to acheive total choline intakes of 450 or 900 mg/d.  To increase the 
study’s validity, the level of choline intake to which you are assigned (i.e., 450 or 
900 mg/d) will not be disclosed.   
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To help us better understand choline requirements and use during pregnancy, a 
small portion of the choline or other relevant nutrients will be labeled from week 6 
to 12.   This label (marker) is safe and has been used many times in studies 
involving babies, young children and pregnant women.  
 
It is important that you eat all of the food we give you and that you eat nothing 
outside what is provided. You will be weighed every week and your calorie intake 
will be modified to ensure that you do not lose or gain more than a couple of 
pounds. 
 
Blood will be taken by a trained phlebotomist before the start of the study and at 
weeks 3, 6, 9, 10 and 12.  The blood will be used to analyze how choline intake, 
folate intake and/or pregnancy influenced biomarkers of status. Also we will use 
the DNA obtained from the blood to analyze how changes in genes influence the 
use of choline and/or folate.  In addition, you will be required to collect your urine 
over a 24 hour period at the beginning of the study (week 0) and at weeks 6, 9, and 
12.  Samples obtained during your participation on this study may be used by the 
investigators (or collaborators) for the purposes of learning more about other 
nutrients (ie., vitamin D and biotin) and how genetic differences affect 
requirements for these nutrients. 
It is possible that other investigators will have access to your blood (including DNA) and urine 
samples; however, the samples will be de-identified (ie, no names will be used). 
 
Risks and benefits:  
We foresee minimal risks as part of your participation in this study. All essential 
nutrients will be provided at or above the recommended intake level for non-
pregnant women.  The choline dosage of 900 mg/d is considered safe (Institute of 
Medicine, National Academy of Science) and falls within the range of choline 
intake consumed by the general population.  
 
It is possible that you will experience some dizziness or ill-feeling during the blood 
draw.  In addition, having blood samples taken always includes a certain low risk 
of infection. To minimize this risk,  blood will be drawn by a trained phlebotomist 
at the human metabolic research unit while you are lying down.   
 
There are no established direct benefits to you. From this study we hope to draw 
conclusions regarding the optimal intake levels of choline and folate for pregnant 
women, potentially benefiting the health of other women and children. 
In the event that you should be injured in the course of this research study, you will 
be provided with necessary medical care in Cayuga Medical Center At Ithaca.  
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You will be paid the dollar amounts 
indicated above in two allotments ($480 
at week 6 and $1140 at week 12) for a 
total of $1620. Should you stop 
participating in the study, you will be 
compensated for the time you have 
spent on the study.   
This statement does not mean that either such medical care or hospitalization, if 
necessary, will be free of charge. 
Compensation:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taking part is voluntary:  
Participating in this study is completely voluntary. If you decide to take part, you 
are free to withdraw at any time; however you will not be eligible to receive 
monetary compensation after ending the study.  You will be able to keep the 
money you have earned up to that point.  
 
The results of your blood tests including the genotyping will be kept 
confidential.  
In any sort of report we make public, we will not include any information that will 
make it possible to identify you. Research records that contain your name (i.e., 
informed consent, health history questionnaire, and the blood chemistry profiles 
and complete blood counts) will be kept in a locked filing cabinet in the office of 
the PI.  All other data (ie., blood measurements, DNA sequences) will be 
identified only by a code (i.e., number). 
 
If you have questions: The main researcher conducting this study is Professor 
Marie Caudill. Please ask any questions you have now. If you have questions later, 
you may contact Marie Caudill at  mac379@cornell.edu or at 607-254-7456. 
Should you contact Professor Caudill via email, please be aware that there is a chance that your 
answers could be read by a third party as internet and email transmissions are neither private or 
secure. 
Week of Study Payment 
1 $50 
2 $60 
3 $70 
4 $80 
5 $100 
6 $120 
7 $140 
8 $160 
9 $180 
10 $200 
11 $220 
12 $240 
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If you have any questions or concerns regarding your rights as a subject in this 
study, you may contact the Institutional Review Board (IRB) at 607-255-5138 or 
access their website at http://www.irb.cornell.edu. You may also report your 
concerns or complaints anonymously through Ethicspoint or by calling toll free at 
1-866-293-3077. Ethicspoint is an independent organization that serves as a liaison 
between the University and the person bringing the complaint so that anonymity 
can be ensured. 
 
You will be given a copy of this form to keep for your records. 
 
Statement of Consent: I have read the above information, and have received 
answers to any questions I asked. I consent to take part in the study.  
 
Your Signature ________________________________ Date _____________ 
 
Study Representative Signature ___________________ Date _____________  
 
This consent form will be kept by the researcher for at least five years beyond the 
end of the study and was approved by University of Cornell’s Institutional Review 
Board for Use of Human Study Participants  on June 5 2008 and by Cayuga 
Medical Center’s Review Board for Use of Human Study Participants on October 
16 2008. 
 
 
 
